

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 February 2003 (20.02.2003)

PCT

(10) International Publication Number  
**WO 03/014340 A2**

- (51) International Patent Classification<sup>7</sup>: C12N 9/00 (74) Agent: GROS, Florent; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).
- (21) International Application Number: PCT/EP02/08654
- (22) International Filing Date: 2 August 2002 (02.08.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/309,957 3 August 2001 (03.08.2001) US
- (71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW.
- (71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ATADJA, Peter, Wisdom [CA/US]; 18 Eastbrook Road, Parsippany, NJ 07054 (US). CUETO, Maria [US/US]; 99 Clifton Terrace, Weehawken, NJ 07086 (US). GAO, Lin [US/US]; 8 Millstone Drive, Morris Plains, NJ 07950 (US).
- Published:  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/014340 A2

(54) Title: HISTONE DEACETYLASE-RELATED GENE AND PROTEIN

(57) Abstract: Disclosed is an HDAC related gene and gene product. In particular, the invention relates to a protein that is highly homologous to known HDACs and referred to herein as HDAC10, nucleic acid molecules that encode such a protein, antibodies that recognize the protein, and methods for diagnosing conditions related to abnormal HDAC10 activity or gene expression.

### **HISTONE DEACETYLASE - RELATED GENE AND PROTEIN**

This invention relates to a histone deacetylase gene and gene product. In particular, the invention relates to a protein that is highly homologous to known mammalian histone deacetylases (HDACs), nucleic acid molecules that encode such a protein, antibodies that recognize the protein, and methods of use which include assays screening for modulators of HDAC activity and for diagnosing conditions related to abnormal HDAC activity, including, for example, abnormal cell proliferation, cancer, atherosclerosis, inflammatory bowel disease, host inflammatory or immune response or psoriasis.

#### **BACKGROUND**

Histone acetylation is a major regulatory mechanism that modulates gene expression by altering the accessibility of transcription factors to DNA. Acetylation of histones is a reversible modification of the free  $\epsilon$ -amino group of lysine that occurs during the assembly of nucleosomes and during DNA synthesis.

HDACs have been shown to play an important role in the regulation of transcription. HDACs function as components of complexes that are involved in transcriptional repression. This is mediated through interactions of HDACs with multi-protein complexes and requires deacetylase activity. Changes in histone acetylation levels also occur during transcriptional activation and silencing. Acetylation of histones is generally associated with transcriptional activity, whereas deacetylation is associated with transcriptional repression.

HDAC complexes may contain the co-repressor mSin3A and mSin3A-associated proteins, silencing mediators NcoR and SMRT, transcriptional repressors, Rb-like proteins p107 and p130, Rb-associated proteins, nuclear hormone receptors, nucleosome remodeling factors, methyl-binding proteins, DNA repair machinery proteins, and the like. Furthermore, HDAC1 has been found to bind directly to YY1 and Sp1 and HDACs 4 and 5 bind to MEF2. In addition, HDACs have been found together in complexes.

Two distinct classes of yeast histone deacetylases have been identified based upon size and sequence. Yeast class I HDACs include Rpd3, Hos1p, and Hos2p. Class II contains yeast HDA1p.

Furthermore, members of these two classes were found to form different complexes. Human HDACs have been classified based upon their similarity to yeast sequences. Class I human HDACs include HDACs 1-3 and 8. Class II HDACs include HDACs 4-7. The deacetylase core of class I HDACs reside in the first ~390 amino acids. Class II HDAC catalytic domains are located in the C-terminal of these peptides, with the exception of HDAC6 that contains a second catalytic domain in the N-terminus. Here we report the isolation and characterization of a new HDAC, referred to herein as HDAC10.

An important approach that has been used to study the function of chromatin acetylation is the use of specific inhibitors of histone deacetylase. Several classes of compounds have been identified that inhibit HDAC. Histone deacetylase inhibitors have been found to have anti-proliferative effects, including induction of G1/S and G2/M cell cycle arrest, differentiation and apoptosis of transformed and normal cells and reversal of transformation. These effects, along with the presence of HDAC in complexes with fusions of unliganded retinoic acid receptors PML-RAR $\alpha$  and PLZF-RAR $\alpha$  indicate a role for HDACs in tumorigenicity. Furthermore, histone deacetylase inhibitors, phenylbutyrate and trichostatin A have shown promise in the treatment of promyelocytic leukemia and several other HDAC inhibitors are being studied as treatments for cancers.

#### SUMMARY OF THE INVENTION

The present invention relates to a novel histone deacetylase designated HDAC10.

In a first aspect, the invention provides an isolated polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:1. Furthermore, the invention provides an isolated polypeptide consisting of an amino acid sequence as set forth in SEQ ID NO:1. The amino acid sequence as set forth in SEQ ID NO:1 shows a considerable degree of homology to that of known members of the family of HDACs in the catalytic domain. For convenience, the polypeptide consisting of the amino acid sequence as set forth in SEQ ID NO:1 will be designated as histone deacetylase 10 or HDAC10. Fragments of the isolated polypeptide having an amino acid sequence as set forth in SEQ ID NO:1 also form a part of the present invention. Preferably, fragments will encompass the catalytic domain, which is predicted to exist between amino acid number 15 to 323. In accordance with this aspect of the invention there are provided novel polypeptides of human origin as well as biologically, diagnostically or therapeutically useful fragments, variants and derivatives thereof, variants and derivatives of the fragments, and analogs of the foregoing.

In a second aspect, the invention provides an isolated DNA comprising a nucleotide sequence that encodes a polypeptide as mentioned above. In particular, the invention provides (1) an isolated DNA comprising the nucleotide sequence as set forth in SEQ ID NO:2; (2) an isolated DNA comprising the nucleotide sequence set forth in SEQ ID NO:3; (3) an isolated DNA capable of hybridizing under high stringency conditions to the nucleotide sequence set forth in SEQ ID NO:2; and (4) an isolated DNA comprising the nucleotide sequence set forth in SEQ ID NO:4. Also provided are nucleic acid sequences comprising at least about 15 bases, preferably at least about 20 bases, more preferably a nucleic acid sequence comprising about 30 contiguous bases of SEQ ID NO:2 or SEQ ID NO:3. Also within the scope of the present invention are nucleic acids that are substantially similar to the nucleic acid with the nucleotide sequence as set forth in SEQ ID NO:2 or SEQ ID NO:3. In a preferred embodiment, the isolated DNA takes the form of a vector molecule comprising at least a fragment of a DNA of the present invention, in particular comprising the DNA consisting of a nucleotide sequence as set forth in SEQ ID NO:2 or SEQ ID NO:3.

A third aspect of the present invention encompasses a method for the diagnosis of conditions associated with abnormal regulation of gene expression which includes, but is not limited to, conditions associated with abnormal cell proliferation, cancer, atherosclerosis, inflammatory bowel disease, or psoriasis in a human which comprises detecting abnormal transcription of messenger RNA transcribed from the natural endogenous human gene encoding the novel polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:1 in an appropriate tissue or cell from a human, wherein such abnormal transcription is diagnostic of the human's affliction with such a condition. In particular, the said natural endogenous human gene encoding the novel polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:1 comprises the genomic nucleotide sequence set forth in SEQ ID NO:4. In one embodiment of the present invention, the diagnostic method comprises contacting a sample of said appropriate tissue or cell or contacting an isolated RNA or DNA molecule derived from that tissue or cell with an isolated nucleotide sequence of at least about 15 - 20 nucleotides in length that hybridizes under high stringency conditions with the isolated nucleotide sequence encoding the novel polypeptide having an amino acid sequence set forth in SEQ ID NO:1.

Another embodiment of the assay aspect of the invention provides a method for the diagnosis of a condition associated with abnormal HDAC10 activity in a human, which comprises measuring the level of deacetylase activity in a certain tissue or cell from a human suffering from such a condition, wherein the presence of an abnormal level of deacetylase activity, relative to the level

thereof in the respective tissue or cell of a human not suffering from a condition associated with abnormal HDAC activity, is diagnostic of the human's suffering from said condition.

In accordance with one embodiment of this aspect of the invention there are provided anti-sense polynucleotides that can regulate transcription of the gene encoding the novel HDAC10; in another embodiment, double stranded RNA is provided that can regulate the transcription of the gene encoding the novel HDAC10.

Another aspect of the invention provides a process for producing the aforementioned polypeptides, polypeptide fragments, variants and derivatives, fragments of the variants and derivatives, and analogs of the foregoing. In a preferred embodiment of this aspect of the invention there are provided methods for producing the aforementioned HDAC10 comprising culturing host cells having incorporated therein an expression vector containing an exogenously-derived nucleotide sequence encoding such a polynucleotide under conditions sufficient for expression of the polypeptide in the host cell, thereby causing expression of the polypeptide, and optionally recovering the expressed polypeptide. In a preferred embodiment of this aspect of the present invention, there is provided a method for producing polypeptides comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:1, which comprises culturing a host cell having incorporated therein an expression vector containing an exogenously-derived polynucleotide encoding a polypeptide comprising or consisting of an amino acid sequence as set forth in SEQ ID NO:1, under conditions sufficient for expression of such a polypeptide in the host cell, thereby causing the production of an expressed polypeptide, and optionally recovering the expressed polypeptide. Preferably, in any of such methods the exogenously derived polynucleotide comprises or consists of the nucleotide sequence set forth in SEQ ID NO:2, the nucleotide sequence set forth in SEQ ID NO:3, or the nucleotide sequence set forth in SEQ ID NO:4. In accordance with another aspect of the invention there are provided products, compositions, processes and methods that utilize the aforementioned polypeptides and polynucleotides for, *inter alia*, research, biological, clinical and therapeutic purposes.

In certain additional preferred embodiments of this aspect of the invention there is provided an antibody or a fragment thereof which specifically binds to a polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:1, i.e., HDAC10. In certain particularly preferred embodiments in this regard, the antibodies are highly selective for human HDAC10 polypeptides or portions of human HDAC10 polypeptides.

In a further aspect, an antibody or fragment thereof is provided that binds to a fragment or portion of the amino acid sequence set forth in SEQ ID NO:1.

In another aspect, methods of treating a condition in a subject, wherein the condition is associated with abnormal HDAC10 gene expression, an increase or decrease in the presence of HDAC10 polypeptide in a subject, or an increase or decrease in the activity of HDAC10 polypeptide, by the administration of an effective amount of an antibody that binds to a polypeptide with the amino acid sequence set out in SEQ ID NO:1, or a fragment or portion thereof to the subject are provided. Also provided are methods for the diagnosis of a disease or condition associated with abnormal HDAC10 gene expression or an increase or decrease in the presence of the HDAC10 in a subject, or an increase or decrease in the activity of HDAC10 polypeptide.

In yet another aspect, the invention provides host cells which can be propagated in vitro, preferably vertebrate cells, in particular mammalian cells, or bacterial cells, which are capable upon growth in culture of producing a polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:1 or fragments thereof, where the cells contain transcriptional control DNA sequences, where the transcriptional control sequences control transcription of RNA encoding a polypeptide with the amino acid sequence according to SEQ ID NO:1 or fragments thereof. This includes, but is not limited to, the propagation of HDAC10 in a plasmid and the production of DNA, RNA or protein in human or insect cells or bacteria using the endogenous HDAC10 promoter or any other transcriptional control sequence.

In yet another aspect of the present invention there are provided assay methods and kits comprising the components necessary to detect above-normal expression of polynucleotides encoding a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:1, or polypeptides comprising an amino acid sequence set forth in SEQ ID NO:1, or fragments thereof, in body tissue samples derived from a patient, such kits comprising e.g., antibodies that bind to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:1, or to fragments thereof, or oligonucleotide probes that hybridize with polynucleotides of the invention. In a preferred embodiment, such kits also comprise instructions detailing the procedures by which the kit components are to be used.

In another aspect, the invention is directed to use of a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:1 or fragment thereof, polynucleotide encoding such a polypeptide or a fragment thereof, or antibody that binds to said polypeptide comprising an amino acid sequence set forth in SEQ ID NO:1 or a fragment thereof in the manufacture of a medicament to treat diseases associated with abnormal HDAC activity or gene expression.

Another aspect is directed to pharmaceutical compositions comprising a polypeptide comprising or consisting of an amino acid sequence set forth in SEQ ID NO:1 or fragment thereof, a polynucleotide encoding such a polypeptide or a fragment thereof, or antibody that binds to such a polypeptide or a fragment thereof, in conjunction with a suitable pharmaceutical carrier, excipient or diluent, for the treatment of diseases associated with abnormal HDAC activity or gene expression.

In another aspect, the invention is directed to methods for the identification of molecules that can bind to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:1 and/or modulate the activity of a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:1 or molecules that can bind to nucleic acid sequences that modulate the transcription or translation of a polynucleotide encoding a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:1. Molecules identified by such methods also fall within the scope of the present invention.

In a related aspect, the invention is directed to use of the novel HDAC10 to identify associated proteins in HDAC biologically relevant complexes. At present, the proteins that associate with HDAC10 are not known. However, these may be characterized by determining whether HDAC10 associates with proteins that have been previously shown to interact with other HDACs (see Introduction). For example, components of HDAC10 complexes may be determined using conventional methods, including co-immunoprecipitation.

In yet another aspect, the invention is directed to methods for the introduction of nucleic acids of the invention into one or more tissues of a subject in need of treatment with the result that one or more proteins encoded by the nucleic acids are expressed and or secreted by cells within the tissue.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of

the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 shows amino acid sequence (SEQ ID NO:1) of HDAC10.

Figure 2 shows the full-length cDNA sequence (SEQ ID NO:2) of HDAC10. The full-length cDNA sequence starts at nucleotide position 1 and ends at nucleotide position 1755.

Figure 3 shows the open reading frame of HDAC10 cDNA sequence (SEQ ID NO:3). The sequence starts at nucleotide position 25 and ends at nucleotide position 1065 as indicated in SEQ ID NO:2.

Figure 4 shows HDAC10 genomic DNA sequence (SEQ ID NO:4).

#### **DETAILED DESCRIPTION OF THE INVENTION**

In practicing the present invention, many conventional techniques in molecular biology, microbiology, and recombinant DNA are used. These techniques are well known to one of ordinary skill in the art. The following abbreviations used throughout the disclosure are listed herein below: histone deacetylase (HDAC), histone deacetylase-like protein (HDLP)

In its broadest sense, the term "substantially similar", when used herein with respect to a nucleotide sequence, means a nucleotide sequence corresponding to a reference nucleotide sequence, wherein the corresponding sequence encodes a polypeptide having substantially the same structure and function as the polypeptide encoded by the reference nucleotide sequence, e.g. where only changes in amino acids not affecting the polypeptide function occur. Desirably the substantially similar nucleotide sequence encodes the polypeptide encoded by the reference nucleotide sequence. The percentage of identity between the substantially similar nucleotide sequence and the reference nucleotide sequence desirably is at least 80%, more desirably at least 85%, preferably at least 90%, more preferably at least 95%, still more preferably at least 98 or 99%. Sequence comparisons are



carried out using Clustalw (see, for example, Higgins, D.G. et al. *Methods Enzymol.* 266:383-402 (1996)). Clustalw alignments were performed using default parameters.

A nucleotide sequence "substantially similar" to reference nucleotide sequence hybridizes to the reference nucleotide sequence in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO<sub>4</sub>, 1 mM EDTA at 50°C with washing in 2X SSC, 0.1% SDS at 50°C, more desirably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO<sub>4</sub>, 1 mM EDTA at 50°C with washing in 1X SSC, 0.1% SDS at 50°C, more desirably still in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO<sub>4</sub>, 1 mM EDTA at 50°C with washing in 0.5X SSC, 0.1% SDS at 50°C, preferably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO<sub>4</sub>, 1 mM EDTA at 50°C with washing in 0.1X SSC, 0.1% SDS at 50°C, more preferably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO<sub>4</sub>, 1 mM EDTA at 50°C with washing in 0.1X SSC, 0.1% SDS at 65°C, yet still encodes a functionally equivalent gene product.

"Elevated transcription of mRNA" refers to a greater amount of messenger RNA transcribed from the natural endogenous human gene encoding the novel polypeptide of the present invention present in an appropriate tissue or cell of an individual suffering from a condition associated with abnormal HDAC10 activity than in a subject not suffering from such a disease or condition; in particular at least about twice, preferably at least about five times, more preferably at least about ten times, most preferably at least about 100 times the amount of mRNA found in corresponding tissues in humans who do not suffer from such a condition. Such elevated level of mRNA may eventually lead to increased levels of protein translated from such mRNA in an individual suffering from a condition associated with abnormal cellular proliferation as compared with a healthy individual. It is also understood that "elevated transcription of mRNA" may refer to a greater amount of messenger RNA transcribed from genes the expression of which is modulated by HDAC10 either alone or in combination with other molecules.

A "host cell," as used herein, refers to a prokaryotic or eukaryotic cell that contains heterologous DNA that has been introduced into the cell by any means, e.g., electroporation, calcium phosphate precipitation, microinjection, transformation, viral infection, and the like.

"Heterologous" as used herein means "of different natural origin" or represent a non-natural state. For example, if a host cell is transformed with a DNA or gene derived from another organism, particularly from another species, that gene is heterologous with respect to that host cell and also with respect to descendants of the host cell which carry that gene. Similarly, heterologous refers to a

nucleotide sequence derived from and inserted into the same natural, original cell type, but which is present in a non-natural state, e.g. a different copy number, or under the control of different regulatory elements.

A "vector" molecule is a nucleic acid molecule into which heterologous nucleic acid may be inserted which can then be introduced into an appropriate host cell. Vectors preferably have one or more origin of replication, and one or more site into which the recombinant DNA can be inserted. Vectors often have convenient means by which cells with vectors can be selected from those without, e.g., they encode drug resistance genes. Common vectors include plasmids, viral genomes, and (primarily in yeast and bacteria) "artificial chromosomes."

"Plasmids" generally are designated herein by a lower case p preceded and/or followed by capital letters and/or numbers, in accordance with standard naming conventions that are familiar to those of skill in the art. Starting plasmids disclosed herein are either commercially available, publicly available on an unrestricted basis, or can be constructed from available plasmids by routine application of well-known, published procedures. Many plasmids and other cloning and expression vectors that can be used in accordance with the present invention are well known and readily available to those of skill in the art. Moreover, those of skill readily may construct any number of other plasmids suitable for use in the invention. The properties, construction and use of such plasmids, as well as other vectors, in the present invention will be readily apparent to those of skill from the present disclosure.

The term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated, even if subsequently reintroduced into the natural system. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.

As used herein, the term "transcriptional control sequence" refers to DNA sequences, such as initiator sequences, enhancer sequences, and promoter sequences, which induce, repress, or otherwise control the transcription of protein encoding nucleic acid sequences to which they are operably linked.

As used herein, "human transcriptional control sequences" are any of those transcriptional control sequences normally found associated with the human gene encoding the novel HDAC10 polypeptide of the present invention as it is found in the respective human chromosome. It is understood that the term may also refer to transcriptional control sequences normally found associated with human genes the expression of which is modulated by HDAC10 either alone or in combination with other molecules.

As used herein, "non-human transcriptional control sequence" is any transcriptional control sequence not found in the human genome.

The term "polypeptide" is used interchangeably herein with the terms "polypeptides" and "protein(s)".

As used herein, a "chemical derivative" of a polypeptide of the invention is a polypeptide of the invention that contains additional chemical moieties not normally a part of the molecule. Such moieties may improve the molecule's solubility, absorption, biological half life, etc. The moieties may alternatively decrease the toxicity of the molecule, eliminate or attenuate any undesirable side effect of the molecule, etc. Moieties capable of mediating such effects are disclosed, for example, in Remington's Pharmaceutical Sciences, 16th ed., Mack Publishing Co., Easton, Pa. (1980).

As used herein, "HDAC10" refers to the amino acid sequences of substantially purified HDAC10 obtained from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine, and preferably human, from any source, whether natural, synthetic, semi-synthetic, or recombinant.

As used herein, "HDAC activity", including "HDAC10 activity" refers to the ability of an HDAC polypeptide to deacetylate histone proteins, including <sup>3</sup>H-labeled H4 histone peptide. Such activity may be measured according to conventional methods. A biologically "active" protein refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule.

The term "agonist", as used herein, refers to a molecule which when bound to HDAC10, causes a change in HDAC10 which modulates the activity of HDAC10. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules that bind to HDAC10.

The terms "antagonist" or "inhibitor" as used herein, refer to a molecule which when bound to HDAC10, blocks or modulates the biological activity of HDAC10. Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates, or any other molecules, natural or synthetic that bind to HDAC10.

The full-length cDNA for HDAC10 is 1755 base pairs in length and it predicts a protein of 347 amino acids. The predicted HDAC10 protein possesses a putative catalytic domain which encompasses approximately 317 amino acids (~6 to 323) based upon alignments of HDAC10 with the putative catalytic domains of all of the other known HDACs. To identify the catalytic domain of HDAC10, Clustalw alignments were performed separately using HDAC10 complete peptide and catalytic domain sequences from class I HDACs (1-3 and 8) or class II HDACs (4-7).

Table 2 below shows the catalytic domain amino acids of HDACs 1-10 that align with histone deacetylase-like protein (HDLP), a bacterial protein that shares 35.2% homology with HDAC1 and possesses deacetylase activity (Finnin, M. S., Doniglan, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., and Pavletich, N. P. (1999) *Nature* 401, 188-193).

Table 2. HDAC catalytic amino acids

HDAC Isoform	Amino acids in the catalytic domains of HDAC isoforms												
HDLP	Pro 22	His 131	His 132	Gly 140	Phe 141	Asp 166	Asp 168	His 170	Asp 173	Phe 198	Asp 258	Leu 265	Tyr 297
HDAC1	Pro	His	His	Gly	Phe	Asp	Asp	His	Asp	Phe	Asp	Leu	Tyr
HDAC2	Pro	His	His	Gly	Phe	Asp	Asp	His	Asp	Phe	Asp	Leu	Tyr
HDAC3	Pro	His	His	Gly	Phe	Asp	Asp	His	Asp	Phe	Asp	Leu	Tyr
HDAC4	Pro	His	His	Gly	Phe	Asp	Asp	His	Asn	Phe	Asp	Leu	His
HDAC5	Pro	His	His	Gly	Phe	Asp	Asp	His	Asn	Phe	Asp	Leu	His
HDAC6-1	Pro	His	His	Gly	Tyr	Asp	Asp	His	Gln	Phe	Asp	Lys	Tyr
HDAC6-2	Pro	His	His	Gly	<i>Phe</i>	Asp	Asp	His	Asn	Phe	Asp	Leu	Tyr
HDAC7	Pro	His	His	Gly	Phe	Asp	Asp	His	Asn	Phe	Asp	Leu	His
HDAC8	Pro	His	His	Gly	Phe	Asp	Asp	His	Asp	Phe	Asp	Met	Tyr
HDAC 9	Pro	His	His	Gly	Phe	Asp	Asp	His	Gln	Phe	Asp	<i>Glu</i>	Tyr
HDAC10	Pro 36	His 142	His 143	Gly 151	Phe 152	Asp 179	Asp 181	His 183	Asn 186	<i>Tyr</i> 209	Asp 261	Leu 268	Tyr 304

Italicized amino acids represent amino acids that are not always conserved.

As a member of the HDAC family, HDAC10 may form biologically relevant complexes with proteins and display functions that have been described for other HDACs. For example, it is likely to be involved in transcription repression as a component of multi-protein complexes that often include transcription co-repressors. Thus, increased activity or expression of HDAC10 may be associated with numerous pathological conditions, including but not limited to, abnormal cell proliferation, cancer, atherosclerosis, inflammatory bowel disease, host inflammatory or immune response, or psoriasis.

Thus, the identification of HDAC10 is useful for designing agents (e.g. antagonists or inhibitors) useful to ameliorate conditions associated with abnormal HDAC activity. These may include, for example, antiproliferative or antiinflammatory agents either through the use of small molecules or proteins (e.g. antibodies) directed against it or its associated proteins in the HDAC transcription repressor complexes. In addition, protein derived from the HDAC10 sequence may also be used as a therapeutic to modify host cell proliferative or inflammatory responses.

To determine the tissue distribution of HDAC10 in human, Northern analyses were performed using a blot containing mRNA isolated from various human tissues. The results indicate that overall expression level of HDAC10 is low and the highest expression level is restricted to brain, heart, skeletal muscle and kidney. Furthermore, real-time PCR experiments reveal that HDAC10 is also highly expressed in testis as well as several human cancerous cell lines. Thus, HDAC10 represents a transcribed gene.

In one aspect, the present invention relates to a novel histone deacetylase (HDAC). As outlined above, HDAC10 is clearly a member of the HDAC family since it is highly similar to other HDAC proteins, especially in the catalytic domain.

The present invention relates to an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1. For example, such a polypeptide may be a fusion protein including the amino acid sequence of the novel HDAC10. In another aspect the present invention relates to an isolated polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:1, which is, in particular, the novel HDAC10.

The invention includes nucleic acid or nucleotide molecules, preferably DNA molecules, in particular encoding the novel HDAC10. Preferably, an isolated nucleic acid molecule, preferably a

DNA molecule, of the present invention encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1. Likewise preferred is an isolated nucleic acid molecule, preferably a DNA molecule, encoding a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:1. Such a nucleic acid or nucleotide, in particular such a DNA molecule, preferably comprises a nucleotide sequence selected from the group consisting of (1) the nucleotide sequence as set forth in SEQ ID NO:2, which is the full-length cDNA sequence encoding the polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:1; (2) the nucleotide sequence set forth in SEQ ID NO:3, which corresponds to the open reading frame of the cDNA sequence set forth in SEQ ID NO:2; (3) a nucleotide sequence capable of hybridizing under high stringency conditions to a nucleotide sequence set forth in SEQ ID NO:3; and (4) the nucleotide sequence set forth in SEQ ID NO:4, which corresponds to the endogenous genomic human DNA encoding the polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:1. Such hybridization conditions may be highly stringent or less highly stringent, as described above. In instances wherein the nucleic acid molecules are deoxyoligonucleotides ("oligos"), highly stringent conditions may refer, e.g., to washing in 6X SSC/0.05% sodium pyrophosphate at 37 °C (for 14-base oligos), 48 °C (for 17-base oligos), 55 °C (for 20-base oligos), and 60 °C (for 23-base oligos). Suitable ranges of such stringency conditions for nucleic acids of varying compositions are described in Krause and Aaronson (1991), *Methods in Enzymology*, 200:546-556.

These nucleic acid molecules may act as target gene antisense molecules, useful, for example, in target gene regulation and/or as antisense primers in amplification reactions of target gene nucleic acid sequences. Further, such sequences may be used as part of ribozyme and/or triple helix sequences, also useful for target gene regulation. Still further, such molecules may be used as components of diagnostic methods whereby the presence of an allele causing a disease associated with abnormal HDAC10 expression or activity, for example, abnormal cell proliferation, cancer, atherosclerosis, inflammatory bowel disease, host inflammatory or immune response, or psoriasis, may be detected.

The invention also encompasses (a) vectors that contain at least a fragment of any of the foregoing nucleotide sequences and/or their complements (i.e., antisense); (b) vector molecules, preferably vector molecules comprising transcriptional control sequences, in particular expression vectors, that contain any of the foregoing coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences; and (c) genetically engineered host cells that contain a vector molecule as mentioned herein or at least a fragment of any of the foregoing

nucleotide sequences operatively associated with a regulatory element that directs the expression of the coding sequences in the host cell. As used herein, regulatory elements include, but are not limited to, inducible and non-inducible promoters, enhancers, operators and other elements known to those skilled in the art that drive and regulate expression. Preferably, host cells can be vertebrate host cells, preferably mammalian host cells, such as human cells or rodent cells, such as CHO or BHK cells. Likewise preferred, host cells can be bacterial host cells, in particular *E.coli* cells.

Particularly preferred is a host cell, in particular of the above described type, which can be propagated in vitro and which is capable upon growth in culture of producing an HDAC10 polypeptide, in particular a polypeptide comprising or consisting of an amino acid sequence set forth in SEQ ID NO:1, wherein said cell contains some fragment or complete sequence of HDAC10 coding sequence in a construct that is controlled by one or more transcriptional control sequences that is not a transcriptional control sequence of the natural endogeneous human gene encoding said polypeptide, wherein said one or more transcriptional control sequences control transcription of a DNA encoding said polypeptide. Possible transcriptional control sequences include, but are not limited to, bacterial or viral promoter sequences.

The invention includes the complete sequence of the gene as well as fragments of any of the nucleic acid sequences disclosed herein. Fragments of the nucleic acid sequences encoding the novel HDAC10 polypeptide may be used as a hybridization probe for a cDNA library to isolate other genes which have a high sequence similarity to the HDAC10 gene or similar biological activity. Probes of this type preferably have at least about 30 bases and may contain, for example, from about 30 to about 50 bases, about 50 to about 100 bases, about 100 to about 200 bases, or more than 200 bases. The probe may also be used to identify a cDNA clone that correspond to a full-length transcript and a genomic clone or clones that contain the complete HDAC10 gene including regulatory and promoter regions, exons, and introns. An example of a screen comprises isolating the coding region of the HDAC10 gene by using the known DNA sequence to synthesize an oligonucleotide probe. Labeled oligonucleotides having a sequence complementary to that of the gene of the present invention may be used to screen a library of human cDNA, genomic DNA or mRNA to determine which members of the library to which the probe hybridizes.

In addition to the gene sequences described above, homologs of such sequences, as may, for example, be present in other species, may be identified and may be readily isolated, without undue experimentation, by molecular biological techniques well known in the art. Furthermore, there may

exist genes at other genetic loci within the genome that encode proteins that have homology to one or more domains of such gene products. These genes may also be identified via similar techniques. For example, the isolated nucleotide sequence of the present invention encoding the novel HDAC10 polypeptide may be labeled and used to screen a cDNA library constructed from mRNA obtained from the organism of interest. Hybridization conditions will be of a lower stringency when the cDNA library is derived from an organism different from the type of organism from which the labeled sequence was derived. Alternatively, the labeled fragment may be used to screen a genomic library derived from the organism of interest, again, using appropriately stringent conditions. Such low stringency conditions will be well known to those of skill in the art, and will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived.

Further, a previously unknown differentially expressed gene-type sequence may be isolated by performing PCR using two degenerate oligonucleotide primer pools designed on the basis of amino acid sequences within the gene of interest. The template for the reaction may be cDNA obtained by reverse transcription of mRNA prepared from human or non-human cell lines or tissue known or suspected to express a differentially expressed gene allele. The PCR product may be subcloned and sequenced to ensure that the amplified sequences represent the sequences of a differentially expressed gene-like nucleic acid sequence. The PCR fragment may then be used to isolate a complete cDNA clone by a variety of conventional methods. For example, the amplified fragment may be labeled and used to screen a bacteriophage cDNA library. Alternatively, the labeled fragment may be used to screen a genomic library.

PCR technology may also be utilized to isolate full-length cDNA sequences. For example, RNA may be isolated, following standard procedures, from an appropriate cellular or tissue source. A reverse transcription reaction may be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis. The resulting RNA/DNA hybrid may then be "tailed" with guanines using a standard terminal transferase reaction, the hybrid may be digested with RNAase H, and second strand synthesis may then be primed with a poly-C primer. Thus, cDNA sequences upstream of the amplified fragment may easily be isolated.

In cases where the gene identified is the normal, or the wild type gene, this gene may be used to isolate mutant alleles of the gene. Isolation of mutant alleles is preferable in processes and disorders that are known or suspected to have a genetic basis. Mutant alleles may be isolated from individuals either known or suspected to have a genotype which contributes to disease symptoms



related to abnormal HDAC activity, including, but not limited to, conditions such as abnormal cell proliferation, cancer, atherosclerosis, inflammatory bowel disease, host inflammatory or immune response, or psoriasis. Mutant alleles and mutant allele products may then be used in the diagnostic assay systems described below.

A cDNA of the mutant gene may be isolated, for example, using PCR, a technique that is well known to those of skill in the art. In this case, the first cDNA strand may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from tissue known or suspected to be expressed in an individual putatively carrying the mutant allele, and by extending the new strand with reverse transcriptase. The second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5' end of the normal gene. Using these two primers, the product is then amplified via PCR, cloned into a suitable vector, and subjected to DNA sequence analysis through methods well known to those of skill in the art. By comparing the DNA sequence of the mutant gene to that of the normal gene, the mutation(s) responsible for the loss or alteration of function of the mutant gene product can be ascertained.

Alternatively, a genomic or cDNA library can be constructed and screened using DNA or RNA, respectively, from a tissue known to or suspected of expressing the gene of interest in an individual suspected of or known to carry the mutant allele. The normal gene or any suitable fragment thereof may then be labeled and used as a probe to identify the corresponding mutant allele in the library. The clone containing this gene may then be purified through methods routinely practiced in the art, and subjected to sequence analysis as described above.

Additionally, an expression library can be constructed utilizing DNA isolated from or cDNA synthesized from a tissue known to or suspected of expressing the gene of interest in an individual suspected of or known to carry the mutant allele. In this manner, gene products made by the putatively mutant tissue may be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against the normal gene product, as described below. In cases where the mutation results in an expressed gene product with altered function (e.g., as a result of a mis-sense mutation), a polyclonal set of antibodies are likely to cross-react with the mutant gene product. Library clones detected via their reaction with such labeled antibodies can be purified and subjected to sequence analysis as described above.

The present invention includes those proteins encoded by nucleotide sequences set forth in any of SEQ ID NOs:2, 3 or 4, in particular, a polypeptide that is or includes the amino acid sequence set out in SEQ ID NO:1, or fragments thereof.

Furthermore, the present invention includes proteins that represent functionally equivalent gene products. Such an equivalent differentially expressed gene product may contain deletions, additions or substitutions of amino acid residues within the amino acid sequence encoded by the differentially expressed gene sequences described, above, but which result in a silent change, thus producing a functionally equivalent differentially expressed gene product. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.

Nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine. Polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. Positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid. "Functionally equivalent," as utilized herein, may refer to a protein or polypeptide capable of exhibiting a substantially similar *in vivo* or *in vitro* activity as the endogenous differentially expressed gene products encoded by the differentially expressed gene sequences described above. "Functionally equivalent" may also refer to proteins or polypeptides capable of interacting with other cellular or extracellular molecules in a manner substantially similar to the way in which the corresponding portion of the endogenous differentially expressed gene product would. For example, a "functionally equivalent" peptide, the sequence of which was modified from the endogenous peptide to achieve "functional equivalency, would be able, in an immunoassay, to diminish the binding of an antibody to the corresponding peptide within the endogenous protein, or the binding to the endogenous protein itself, against which the antibody was raised. An equimolar concentration of the functionally equivalent peptide will diminish the aforesaid binding of the corresponding peptide by at least about 5%, preferably between about 5% and 10%, more preferably between about 10% and 25%, even more preferably between about 25% and 50%, and most preferably between about 40% and 50%.

The polypeptides of the present invention may be produced by recombinant DNA technology using techniques well known in the art. Therefore, there is provided a method of producing a polypeptide of the present invention, which method comprises culturing a host cell having

incorporated therein an expression vector containing an exogenously-derived polynucleotide encoding a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:1 under conditions sufficient for expression of the polypeptide in the host cell, thereby causing the production of the expressed polypeptide. Optionally, said method further comprises recovering the polypeptide produced by said cell. In a preferred embodiment of such a method, said exogenously-derived polynucleotide encodes a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO:1. Preferably, said exogenously-derived polynucleotide comprises the nucleotide sequence as set forth in any of SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4. In case of using the nucleotide sequence set forth in SEQ ID NO:3, i.e. the open reading frame, the sequence, when inserted into a vector, may be followed by one or more appropriate translation stop codons, preferably by the natural endogenous stop codon TGA beginning at nucleotide 1066 in the cDNA sequence.

Thus, methods for preparing the polypeptides and peptides of the invention by expressing nucleic acid encoding respective nucleotide sequences are described herein. Methods which are well-known to those skilled in the art can be used to construct expression vectors that contain protein coding sequences and appropriate transcriptional/translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination. Alternatively, RNA capable of encoding differentially expressed gene protein sequences may be chemically synthesized using, for example, synthesizers.

A variety of host-expression vector systems may be utilized to express the HDAC10 gene coding sequences of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, exhibit the HDAC10 gene protein of the invention *in situ*. These include, but are not limited to, microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing differentially expressed gene protein coding sequences; yeast (e.g. *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing the differentially expressed gene protein coding sequences; insect cell systems infected or transfected with recombinant virus expression vectors (e.g., baculovirus) containing the differentially expressed gene protein coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant vectors, including plasmids, (e.g., Ti plasmid) containing protein coding sequences; or mammalian cell systems (e.g. COS, CHO, BHK, 293, 3T3)

harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothioneine promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter, or the CMV promoter).

Expression of the HDAC10 of the present invention by a cell from an HDAC10 encoding gene that is native to the cell can also be performed. Such methods are known in the art. Cells that have been induced to express HDAC10 can be implanted into a desired tissue in a living animal in order to increase the local concentration of HDAC10 in the tissue.

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the protein being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of antibodies or to screen peptide libraries, for example, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. In this respect, fusion proteins comprising hexahistidine tags may be used, such as EpiTag vectos including pCDNA3.1/His (Invitrogen, Carlsbad, CA). Other vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which the protein coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors; and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene protein can be released from the GST moiety. Fusion proteins containing Flag tags, such as 3X Flag (Sigma, St. Louis, MO) or myc tags, for example pCDNA3.1/myc-His (Invitrogen, Carlsbad, CA) may be used. These fusions allow coimmunoprecipitation and Western detection of proteins for which antibodies are not yet available.

Promoter regions from any desired gene can be introduced into vectors containing a reporter transcription unit, such as a chloramphenicol acetyl transferase ("CAT"), or the luciferase transcription unit, which also lack a promoter region. Restriction site or sites in the vector can be used for introducing a candidate promoter fragment; i.e., a fragment that may contain a promoter. For example, introduction into the vector of a promoter-containing fragment at the restriction site upstream of the cat gene engenders production of CAT activity, which can be detected by standard CAT assays. Vectors suitable to this end are well known and readily available. Two such vectors are

pKK232-8 and pCM7. Thus, promoters for expression of polynucleotides of the present invention include not only well-known and readily available promoters, but also promoters that readily may be obtained by the foregoing technique, using a reporter gene.

Among known bacterial promoters suitable for expression of polynucleotides and polypeptides in accordance with the present invention are the *E. coli* lacI and lacZ promoters, the T3 and T7 promoters, the T5 tac promoter, the lambda PR, PL promoters and the trp promoter. Among known eukaryotic promoters suitable in this regard are the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus ("RSV"), and metallothionein promoters, such as the mouse metallothionein-I promoter. For example, a plasmid construct could contain a HDAC10 transcriptional control sequence fused to a reporter transcription unit that encodes the coding region of  $\beta$ -Galactosidase, chloramphenicol acetyltransferase, green fluorescent protein or luciferase. This construct could be used to screen for small molecules that modulate HDAC10 transcription. Such molecules are potential therapeutics. Furthermore, using fluorescence microscopy or Biophotonic *in vivo* imaging, a technology that produces visual and quantitative measurements in real time (Xenogen, Palo Alto, CA), expression of a fluorescent HDAC10 reporter gene could be examined to determine the effects of an HDAC10 therapeutic in mammalian cells or xenografts. Changes in these reporters in normal, diseased or drug-treated tissue or cells would be indicators of changes in HDAC10 expression or activity.

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is one of several insect systems that can be used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of the coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect *Spodoptera frugiperda* cells in which the inserted gene is expressed.

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo*

recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the desired protein in infected hosts (e.g., See Logan & Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659). Specific initiation signals may also be required for efficient translation of inserted gene coding sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire gene, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of the gene coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc.. Other common systems are based on SV40, retrovirus or adeno-associated virus. Selection of appropriate vectors and promoters for expression in a host cell is a well known procedure and the requisite techniques for expression vector construction, introduction of the vector into the host and expression in the host per se are routine skills in the art. Generally, recombinant expression vectors will include origins of replication, a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence, and a selectable marker to permit isolation of vector containing cells after exposure to the vector.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, etc. and are well known to one of skill in the art.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines that stably express a differentially expressed protein product of a gene may be

engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines that express the differentially expressed gene protein. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the expressed protein.

A number of selection systems may be used, including but not limited to, the herpes simplex virus thymidine kinase, hypoxanthine-guanine phosphoribosyltransferase and adenine phosphoribosyltransferase genes can be employed in tk<sup>-</sup>, hgprt<sup>-</sup> or aprt<sup>-</sup> cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate, gpt, which confers resistance to mycophenolic acid; neo, which confers resistance to the aminoglycoside G-418; and hyg<sup>r</sup>, which confers resistance to hygromycin genes.

An alternative fusion protein system allows for the ready purification of non-denatured fusion proteins expressed in human cell lines. In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni<sup>2+</sup> nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

When used as a component in assay systems such as those described below, a protein of the present invention may be labeled, either directly or indirectly, to facilitate detection of a complex formed between the protein and a test substance. Any of a variety of suitable labeling systems may be used including, but not limited to, radioisotopes such as <sup>125</sup>I; enzyme labeling systems that generate a detectable calorimetric signal or light when exposed to substrate; and fluorescent labels.

Where recombinant DNA technology is used to produce a protein of the present invention for such assay systems, it may be advantageous to engineer fusion proteins that can facilitate labeling, immobilization, detection and/or isolation

Indirect labeling involves the use of a protein, such as a labeled antibody, which specifically binds to a polypeptide of the present invention. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments and fragments produced by an Fab expression library.

In another embodiment, nucleic acids comprising a sequence encoding HDAC10 protein or functional derivative thereof, may be administered to promote normal biological function, for example, normal transcriptional regulation, by way of gene therapy. Gene therapy refers to therapy performed by the administration of a nucleic acid to a subject. In this embodiment of the invention, the nucleic acid produces its encoded protein that mediates a therapeutic effect by promoting normal transcriptional regulation.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

In a preferred aspect, the therapeutic comprises a HDAC10 nucleic acid that is part of an expression vector that expresses a HDAC10 protein or fragment or chimeric protein thereof in a suitable host. In particular, such a nucleic acid has a promoter operably linked to the HDAC10 coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment, a nucleic acid molecule is used in which the HDAC10 coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the HDAC10 nucleic acid.

Delivery of the nucleic acid into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vector, or indirect, in which case, cells are first transformed with the nucleic acid *in vitro*, then transplanted into the patient. These two approaches are known, respectively, as *in vivo* or *ex vivo* gene therapy.

In a specific embodiment, the nucleic acid is directly administered *in vivo*, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, for example, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by infection using a defective or



attenuated retroviral or other viral vector, or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering it in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor. Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination

In a specific embodiment, a viral vector that contains the HDAC10 nucleic acid is used. For example, a retroviral vector can be used. These retroviral vectors have been modified to delete retroviral sequences that are not necessary for packaging of the viral genome and integration into host cell DNA. The HDAC10 nucleic acid to be used in gene therapy is cloned into the vector, which facilitates delivery of the gene into a patient.

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Adeno-associated virus (AAV) has also been proposed for use in gene therapy.

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or

bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. In a preferred embodiment, epithelial cells are injected, e.g., subcutaneously. In another embodiment, recombinant skin cells may be applied as a skin graft onto the patient. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy, a HDAC10 nucleic acid is introduced into the cells such that it is expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem-and/or progenitor cells that can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention. Such stem cells include but are not limited to hematopoietic stem cells (HSC), stem cells of epithelial tissues such as the skin and the lining of the gut, embryonic heart muscle cells, liver stem cells, and neural stem cells.

Epithelial stem cells (ESCs) or keratinocytes can be obtained from tissues such as the skin and the lining of the gut by known procedures. In stratified epithelial tissue such as the skin, renewal occurs by mitosis of stem cells within the germinal layer, the layer closest to the basal lamina. Stem cells within the lining of the gut provide for a rapid renewal rate of this tissue. ESCs or keratinocytes obtained from the skin or lining of the gut of a patient or donor can be grown in tissue culture. If the ESCs are provided by a donor, a method for suppression of host versus graft reactivity (e.g., irradiation, drug or antibody administration to promote moderate immunosuppression) can also be used.

With respect to hematopoietic stem cells (HSC), any technique which provides for the isolation, propagation, and maintenance in vitro of HSC can be used in this embodiment of the invention. Techniques by which this may be accomplished include (a) the isolation and establishment of HSC cultures from bone marrow cells isolated from the future host, or a donor, or (b) the use of previously established long-term HSC cultures, which may be allogeneic or xenogeneic. Non-autologous HSC are used preferably in conjunction with a method of suppressing transplantation immune reactions of the future host/patient. In a particular embodiment of the present invention, human bone marrow cells can be obtained from the posterior iliac crest by needle aspiration. In a preferred embodiment of the present invention, the HSCs can be made highly enriched or in substantially pure form. This enrichment can be accomplished before, during, or after long-term culturing, and can be done by any techniques known in the art. Long-term cultures of bone marrow cells can be established and maintained by using, for example, modified Dexter cell culture techniques or Witlock-Witte culture techniques.

In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.

A further embodiment of the present invention relates to a purified antibody or a fragment thereof which specifically binds to a polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:1 or to a fragment of said polypeptide. A preferred embodiment relates to a fragment of such an antibody, which fragment is an Fab or F(ab')<sub>2</sub> fragment. In particular, the antibody can be a polyclonal antibody or a monoclonal antibody.

Methods for the production of antibodies capable of specifically recognizing one or more differentially expressed gene epitopes are known to one of ordinary skill in the art. Such antibodies may include, but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')<sub>2</sub> fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Such antibodies may be used, for example, in the detection of a fingerprint, target, gene in a biological sample, or, alternatively, as a method for the inhibition of abnormal target gene activity. Thus, such antibodies may be utilized as part of disease treatment methods, and/or may be used as part of diagnostic techniques whereby patients may be tested for abnormal levels of the HDAC10 polypeptide, or for the presence of abnormal forms of the HDAC10 polypeptide.

For the production of antibodies to the HDAC10 polypeptide, various host animals may be immunized by injection with the HDAC10 polypeptide, or a portion thereof. Such host animals may include but are not limited to rabbits, mice, and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*.

Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen, such as target gene product, or an antigenic functional derivative thereof. For the production of polyclonal antibodies, host animals such as those described above, may be immunized by injection with the HDAC10 polypeptide, or a portion thereof, supplemented with adjuvants as also described above.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo makes this the presently preferred method of production.

In addition, techniques developed for the production of "chimeric antibodies" by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable or hypervariable region derived from a murine mAb and a human immunoglobulin constant region.

Alternatively, techniques described for the production of single chain antibodies can be adapted to produce differentially expressed gene-single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

Most preferably, techniques useful for the production of "humanized antibodies" can be adapted to produce antibodies to the polypeptides, fragments, derivatives, and functional equivalents disclosed herein.

Antibody fragments that recognize specific epitopes may be generated by known techniques. For example, such fragments include but are not limited to: the  $F(ab')_2$  fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the  $F(ab')_2$  fragments. Alternatively, Fab expression libraries may be constructed (Huse et al., 1989, Science, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

An antibody of the present invention can be preferably used in a method for the diagnosis of a condition associated with abnormal HDAC10 expression or activity, for example, abnormal cell proliferation, cancer, atherosclerosis, inflammatory bowel disease, host inflammatory or immune response, or psoriasis, in a human which comprises: measuring the amount of a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1, or fragments thereof, in an appropriate tissue or cell from a human suffering from a condition associated with abnormal HDAC10 activity, wherein the presence of an elevated amount of said polypeptide or fragments thereof, relative to the amount of said polypeptide or fragments thereof in the respective tissue from a human not suffering from a condition associated with abnormal HDAC10 activity is diagnostic of said human's suffering from such condition. Such a method forms a further embodiment of the present invention. Preferably, said detecting step comprises contacting said appropriate tissue or cell with an antibody which

specifically binds to a polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:1 or a fragment thereof and detecting specific binding of said antibody with a polypeptide in said appropriate tissue or cell, wherein detection of specific binding to a polypeptide indicates the presence of a polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:1 or a fragment thereof.

Particularly preferred, for ease of detection, is the sandwich assay, of which a number of variations exist, all of which are intended to be encompassed by the present invention.

For example, in a typical forward assay, unlabeled antibody is immobilized on a solid substrate and the sample to be tested brought into contact with the bound molecule. After a suitable period of incubation time sufficient to allow formation of an antibody-antigen binary complex, a second antibody, labeled with a reporter molecule capable of inducing a detectable signal, is then added and incubated, allowing time sufficient for the formation of a ternary complex of antibody-antigen-labeled antibody. Any unreacted material is washed away, and the presence of the antigen is determined by observation of a signal, or may be quantitated by comparing with a control sample containing known amounts of antigen. Variations on the forward assay include the simultaneous assay, in which both sample and antibody are added simultaneously to the bound antibody, or a reverse assay in which the labeled antibody and sample to be tested are first combined, incubated and added to the unlabeled surface bound antibody. These techniques are well known to those skilled in the art, and the possibility of minor variations will be readily apparent. As used herein, "sandwich assay" is intended to encompass all variations on the basic two-site technique. For the immunoassays of the present invention, the only limiting factor is that the labeled antibody be an antibody that is specific for the HDAC10 polypeptide or a fragment thereof.

The most commonly used reporter molecules in this type of assay are either enzymes, fluorophore- or radionuclide-containing molecules. In the case of an enzyme immunoassay an enzyme is conjugated to the second antibody, usually by means of glutaraldehyde or periodate. As will be readily recognized, however, a wide variety of different ligation techniques exist, which are well known to the skilled artisan. Commonly used enzymes include horseradish peroxidase, glucose oxidase, beta-galactosidase and alkaline phosphatase, among others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable color change. For example, p-nitrophenyl phosphate is suitable for use with alkaline phosphatase conjugates; for peroxidase conjugates, 1,2-phenylenediamine or toluidine are

commonly used. It is also possible to employ fluorogenic substrates, which yield a fluorescent product rather than the chromogenic substrates noted above. A solution containing the appropriate substrate is then added to the tertiary complex. The substrate reacts with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, to give an evaluation of the amount of HDAC10 which is present in the serum sample.

Alternately, fluorescent compounds, such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labeled antibody absorbs the light energy, inducing a state of excitability in the molecule, followed by emission of the light at a characteristic longer wavelength. The emission appears as a characteristic color visually detectable with a light microscope. Immunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotopes, chemiluminescent or bioluminescent molecules may also be employed. It will be readily apparent to the skilled artisan how to vary the procedure to suit the required use.

This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. In particular, the invention relates to a method for the diagnosis of a condition associated with abnormal HDAC10 expression or activity, for example, abnormal cell proliferation, cancer, atherosclerosis, inflammatory bowel disease, host inflammatory or immune response, or psoriasis in a human which comprises: detecting elevated transcription of messenger RNA transcribed from the natural endogeneous human gene encoding the polypeptide consisting of an amino acid sequence set forth in SEQ ID NO:1 in an appropriate tissue or cell from a human, wherein said elevated transcription is diagnostic of said human's suffering from the condition associated with abnormal HDAC10 expression or activity. In particular, said natural endogeneous human gene comprises the nucleotide sequence set forth in SEQ ID NO:4. In a preferred embodiment such a method comprises contacting a sample of said appropriate tissue or cell or contacting an isolated RNA or DNA molecule derived from that tissue or cell with an isolated nucleotide sequence of at least about 20 nucleotides in length that hybridizes under high stringency conditions with the isolated nucleotide sequence encoding a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO:1.

Detection of a mutated form of the gene characterized by the polynucleotide of SEQ ID NO:4 which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a

diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

Nucleic acids, in particular mRNA, for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled nucleotide sequences which encode the HDAC10 polypeptide of the present invention. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method. In another embodiment, an array of oligonucleotide probes comprising nucleotide sequence encoding the HDAC10 polypeptide of the present invention or fragments of such a nucleotide sequence can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability.

The diagnostic assays offer a process for diagnosing or determining a susceptibility to disease through detection of mutation in the HDAC10 gene by the methods described. In addition, such diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit which comprises:



- 32 -

- (a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO:2, 3 or 4, or a fragment thereof;
- (b) a nucleotide sequence complementary to that of (a);
- (c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:1 or a fragment thereof; or
- (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:1.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly to a disease or condition associated with abnormal HDAC10 expression or activity, for example, abnormal cell proliferation, cancer, atherosclerosis, inflammatory bowel disease, host inflammatory or immune response, or psoriasis.

The nucleotide sequences of the present invention are also valuable for chromosome localization. The sequence is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene-associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

An additional embodiment of the invention relates to the administration of a pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, excipient or diluent, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of HDAC10, antibodies to that polypeptide, mimetics, agonists, antagonists, or inhibitors of HDAC10 function. The compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The

compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

In addition, any of the therapeutic proteins, antagonists, antibodies, agonists, antisense sequences or vectors described above may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects. Antagonists and agonists of HDAC10 may be made using methods that are generally known in the art.

The pharmaceutical compositions encompassed by the invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-articular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and

tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of the HDAC10, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example HDAC10 or fragments thereof, antibodies of HDAC10, agonists, antagonists or inhibitors of HDAC10, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED<sub>50</sub> (the dose therapeutically effective in 50% of the population) and LD<sub>50</sub> (the dose lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD<sub>50</sub>/ED<sub>50</sub>. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED<sub>50</sub> with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc. Pharmaceutical formulations suitable for oral administration of proteins are known in the art.

All patent applications, patents and literature references cited herein are hereby incorporated by reference in their entirety.

The following Examples illustrate the present invention, without in any way limiting the scope thereof.

Example 1: HDAC10 protein expression *in vivo*

An expression vector containing HDAC10's coding sequences plus the Flag-epitope encoding sequences at the C-terminus is transfected into 293 embryonic kidney cells using the GenePORTER2 transfection reagent (Gene Therapy System Inc., San Diego, CA). Forty-eight hr. after transfection, cell lysates are prepared from the transfected cells and 10 µg of total protein is subjected to SDS-PAGE on a 10% Tris-glycine gel. The proteins are then transferred onto a PVDF membrane and probed with an anti-Flag antibody, followed by a secondary antibody that is conjugated with horseredish peroxidase, which allows for detection of signal using enhanced luminescence reagents. The anti-Flag antibody detects the HDAC10-Flag fusion protein as a single band of 39 kDa in size, which agrees with the estimated size of HDAC10 protein based on its amino acid composition.

Example 2: Distribution of HDAC10 mRNA in normal human tissues and cancer cell lines

A multiple human tissue Northern blot is purchased from Clontech (Palo Alto, CA). A  $^{32}\text{P}$ -labeled probe corresponding to HDAC10 cDNA (nucleotide no.181 to no.1122) is prepared using the Rediprime DNA labeling system (Amersham Pharmacia Biotech) according to the manufacturer's instructions. The Northern blot is pre-hybridized and hybridized in the presence of the  $^{32}\text{P}$ -labeled probe under stringent conditions according to the manufacturer's protocol. A probe corresponding to human actin cDNA (Clontech) is used as a control for the relative amount of mRNA in each lane. Results of Northern analyses indicate that there are two spliced variant forms of HDAC10 mRNA, one is ~1.7kb, which agrees with the size of the full-length cDNA (SEQ ID NO:2); the other is ~3.2kb and is expressed at a higher level. The larger transcript agrees with the size of a *Macac fascicularis* brain cDNA clone (GenBank™ accession #AB052134), which encodes a truncated HDAC10 polypeptide (minus the first 29 amino acids) with 3 conservative amino acid substitutions. Northern analyses also show that overall expression level of HDAC10 mRNA is low and high expression level is restricted to brain, heart, skeletal muscle and kidney. These findings imply that the HDAC10 gene is expressed in normal human tissues and that HDAC10's function may be tissue-specific.

In addition to Northern blotting, the Real-time PCR technique is used to examine HDAC10 mRNA distribution in normal human tissues as well as several human cancer cell lines. These experiments confirm findings of the Northern analyses; in addition, they reveal high expression level of HDAC10 in testis. Furthermore, our data indicate that large amount of HDAC10 mRNA is also found in a non-small cell lung carcinoma cell line, a rhabdomyosarcoma muscle tumor line, a urinary bladder cancer cell line and an osteosarcoma cell line. Taken together, these results indicate that HDAC10 may function not only in normal human tissues, but also in the development and/or maintenance of human cancers.

Example 3: *In vitro* HDAC enzyme assay

To determine whether the putative HDAC "10" is an active deacetylase, transfected Flag epitope-tagged recombinant HDAC10 is used to measure the ability of HDAC10 to deacetylate histone H4 peptide. Enzymatic activity may be determined according to conventional methods, such as the following techniques:

*Preparation of HDAC10-Flag expression vector.* Using conventional techniques in molecular biology, a Flag-epitope sequence is added to the C-terminus of HDAC10 coding sequences (SEQ ID NO:3) by PCR. The PCR primers are:

Forward: 5'-GAGGATCCACCAT**GTCTACACACA**ACCCAGCTG- 3'

Reverse: 5'-GCGTCTAGACT**ACTTGT**CATCGTCGTCCTTGTAATCAGCCCGGGGC-  
ACTGCAGGGGGAAG- 3'.

The BamHI and XbaI restriction enzyme cutting sites are underlined, the ATG translational start site is bolded in the forward primer and the Flag-epitope endcoding sequences are bolded in the reverse primer. The Flag-tagged HDAC10 PCR fragment is cloned into the pcDNA3.1(+) expression vector between the BamHI and XbaI sites.

*Transfection and Immunoprecipitation.* Approximately  $1 \times 10^7$  293 human embryonic kidney cells were grown in a 15-cm<sup>2</sup> plate (~50% confluent) on the day of transfection. GenePORTER transfection reagent (Gene Therapy Systems, Inc., San Diego, CA) is used to transfect 30 µg of plasmid DNA per plate of cells according to manufacturer's instructions. Forty-eight hr after transfection, cells are washed twice with ice-cold phosphate-buffered saline (PBS) and resuspended in 1 mL ice-cold lysis buffer (50 mM Tris-Cl, pH 7.4, 120 mM NaCl, 0.5 mM EDTA, 0.5% NP-40) supplemented with EDTA-free protease inhibitor complete (Roche Molecular Biochemicals, Indianapolis, IN). The lysate is incubated at 4°C for 20 min on a rotator, followed by spinning at 12,000 x g for 20 min at 4°C. The soluble supernatant is collected and used for immunoprecipitation with 20 µl anti-FLAG M2 affinity gel (Sigma, Saint Louis, MI) at 4°C overnight. As a negative control, 1 mL lysis buffer is used instead of the cell lysate. The immunoprecipitated complex is pelleted by centrifugation and washed three times with 1 mL ice-cold lysis buffer, four times with lysis buffer containing 1 M NaCl and three times with 1 mL HDAC assay buffer (10 mM Tris-Cl, pH 8.0, 10 mM NaCl, 10% glycerol).

*In vitro HDAC enzyme assay.* The immunoprecipitated complex is suspended in 30 µl HDAC assay buffer containing 30,000 cpm of the acetylated histone H4 peptide. Histone deacetylase activity is determined after incubation at 37°C for 3 hr as described (Emiliani, S., Fischle, W., Van Lint, C., Al-Abed, Y., and Verdin, E. (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95, 2795-2800).

Results of the *in vitro* HDAC enzyme assays show that cells expressing the HDAC10-Flag fusion protein contain 2.5-3 fold higher enzyme activity than cells expressing the pcDNA3.1(+) vector alone. Therefore, HDAC10 is likely to contain intrinsic histone deacetylase enzyme activity.

Example 4: Identification of HDAC10 associated protein

Using conventional methods, proteins in the same complex as HDAC10 may be identified by their ability to coimmunoprecipitate with HDAC10-Flag fusion protein. The HDAC10-Flag expression vector or the vector alone is transfected into 293 cells and cell lysates are prepared as described above. The lysates are precleared with Sepharose A/G plus agarose beads, followed by immunoprecipitation using anti-Flag antibody at 4°C overnight on a rotator as described in example 3. The immune complexes are washed twice with ice-cold lysis buffer (see example 3), twice with lysis buffer containing 1 M NaCl and twice with PBS. The final complexes are separated by SDS-PAGE on 10% Tris-glycine gels, transferred onto a PVDF membrane and probed with antibodies against known HDAC-associated proteins or other HDACs. Conversely, the immunoprecipitation could be done using antibodies of choice, and the resulting immune complexes could be probed with anti-Flag antibody.



What is claimed is:

1. An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1.
2. An isolated DNA comprising a nucleic acid sequence that encodes the polypeptide of claim 1.
3. A vector molecule comprising at least a fragment of the isolated DNA according to claim 2.
4. The vector molecule according to claim 3 comprising transcriptional control sequences.
5. A host cell comprising the vector molecule according to claim 4.
6. The isolated DNA according to claim 2, comprising a nucleotide sequence selected from the group consisting of (1) the nucleotide sequence set forth in SEQ ID NO:2; (2) the nucleotide sequence set forth in SEQ ID NO:3; (3) a nucleotide sequence capable of hybridizing under high stringency conditions to a nucleotide sequence set forth in SEQ ID NO:3; and (4) the nucleotide sequence set forth in SEQ ID NO:4.
7. A vector molecule comprising the isolated DNA molecule according to claim 6, or a fragment thereof.
8. The vector molecule according to claim 7 comprising transcriptional control sequences.
9. A host cell comprising the vector molecule according to claim 8.
10. A host cell which can be propagated *in vitro* and which is capable upon growth in culture of expressing HDAC 10, wherein said cell comprises at least one transcriptional control sequence that is not a transcriptional control sequence of the natural endogenous human gene encoding HDAC 10, wherein said one or more transcriptional control sequences control transcription of a DNA encoding HDAC 10.
11. A method for the diagnosis of a condition associated with abnormal regulation of gene expression which includes, abnormal cell proliferation, cancer, atherosclerosis, inflammatory bowel

disease, host inflammatory or immune response, or psoriasis in a human which comprises: detecting abnormal transcription of messenger RNA transcribed from the natural endogeneous human gene encoding HDAC 10 in an appropriate tissue or cell from a human, wherein said abnormal transcription is diagnostic of said condition.

12. The method of claim 11, wherein said natural endogeneous human gene comprises the nucleotide sequence set forth in SEQ ID NO:4.

13. A method for the diagnosis of a condition associated with abnormal HDAC10 expression or activity in a human which comprises:

measuring the amount of HDAC 10, or fragments thereof, in an appropriate tissue or cell from a human suffering from said condition wherein the presence of an abnormal amount of said polypeptide or fragments thereof, relative to the amount of said polypeptide or fragments thereof in the respective tissue from a human not suffering from said condition associated with abnormal HDAC10 expression or activity is diagnostic of said human's suffering from said condition.

14. The method of claim 13, wherein said detecting step comprises contacting said appropriate tissue or cell with an antibody which specifically binds to a polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:1 or a fragment thereof and detecting specific binding of said antibody with a polypeptide in said appropriate tissue or cell, wherein detection of specific binding to a polypeptide indicates the presence of a polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:1 or a fragment thereof.

15. An antibody or a fragment thereof which specifically binds to a polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:1 or to a fragment of said polypeptide.

16. An antibody fragment according to claim 15 which is an Fab or F(ab')<sub>2</sub> fragment.

17. An antibody according to claim 15 which is a polyclonal antibody.

18. An antibody according to claim 15 which is a monoclonal antibody.

19. A method for producing an HDAC 10 polypeptide, which method comprises:

culturing a host cell having incorporated therein an expression vector comprising an exogenously-derived polynucleotide encoding a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:1 or a nucleotide sequence capable of hybridizing under high stringency conditions to a complement of said polynucleotide, under conditions sufficient for expression of the polypeptide in the host cell, thereby causing the production of the expressed polypeptide.

20. The method according to claim 19, wherein said exogenously-derived polynucleotide hybridizes under stringent conditions to the nucleotide sequence as set forth in SEQ ID NO:2.
21. The method according to claim 19, wherein said exogenously-derived polynucleotide comprises the nucleotide sequence as set forth in SEQ ID NO:3.
22. A histone deacetylase which comprises the catalytic domain of HDAC 10.

## SEQ ID NO:1

MLHTTQLYQH VPETPWPIVY SPRYNITFMG LEKLHPFDAG KWGKVINFLK EEKLLSDSML 60  
 VEAREASEED LLVVHTRRYL NELKWSFAVA TITEIPPVIF LPNFLVQRKV LRPLRTQTGG 120  
 TIMAGKLAVE RGWAINVGGG FHCSSDRGG GFCAYADITL AIKFLFERVE GISRATIIDL 180  
 DAHQGNNGHER DFMDDKRVYI MDVYNRHIYP GDRFAKQAIR RKVELEWTE DDEYLDKVER 240  
 NIKKSLQEHL PDVVVYNAGT DILEGDRLLGG LSISPAGIVK RDELVFRMVR GRRVPILMVT 300  
 SGGYQKRTAR IIADSILNLF GLGLIGPESP SVSAQNSDTP LLPPAVP

## SEQ ID NO:2

1 agctttggga gggccggccc cggtatgcta cacacaaccc agctgtacca gcatgtgcca  
 61 gagacaccct ggccaatcgt gtactcgccg cgctacaaca tcaccttcat gggcctggag  
 121 aagctgcatc cctttgatgc cggaaaatgg ggcaaagtga tcaatttcct aaaagaagag  
 181 aagcttctgt ctgacagcat gctggtggag gcgcgggagg cctcggagga ggacctgctg  
 241 gtggtgcaca cgaggcgcta tcttaatgag ctcaagtggc cctttgctgt tgctaccatc  
 301 acagaaatcc ccccggttat ctctctccc aacttccttg tgcagaggaa ggtgctgagg  
 361 ccccttcgga ccagacagg aggaaccata atggcgggga agctggctgt ggagcgaggc  
 421 tgggccatca acgtgggggg tggttccac cactgctcca gcgaccgtgg cgggggcttc  
 481 tgtgcctatg cggacatcac gctcgccatc aagtttctgt ttgagcgtgt ggagggcatc  
 541 tccagggcta ccatcattga tcttgatgcc catcagggca atgggcatga gcgagacttc  
 601 atggacgaca agcgtgtgta catcatggat gtctacaacc gccacatcta cccaggggac  
 661 cgctttgcca agcaggccat caggcggaag gtggagctgg agtggggcac agaggatgat  
 721 gagtacctgg ataaggtgga gaggaacatc aagaaatccc tccaggagca cctgcccagc  
 781 gtggtggtat acaatgcagg caccgacatc ctcgaggggg accgccttgg ggggctgtcc  
 841 atcagcccag cgggcacgtg gaagcgggat gagctggtgt tccggatggt ccgtggccgc  
 901 cgggtgcccc tccttatggt gacctcaggc gggtagcaga agcgcacagc ccgcatcatt  
 961 gctgactcca tacttaatct gtttggcctg gggctcattg ggctgagtc acccagcgtc  
 1021 tccgcacaga actcagacac accgctgctt cccctgcag tgcctgacc cttgctgccc  
 1081 tgcctgtcac gtggccctgc ctatccgccc cttagtgctt tttgttttct aacctcatgg  
 1141 ggtggtggag gcagccttca gtgagcatgg aggggcaggg ccacccctgg ctggggcctg  
 1201 gagctggccc ttcctctact ttccctgctt ggaagccaga agggcttgag gcctctatgg  
 1261 gtgggggcag aaggcagagc ctgtgtccca gggggaccca cacgaagtca ccagcccata  
 1321 ggtccaggga ggcaggcagt taactgagaa ttggagagga caggctaggt cccaggcaca  
 1381 gcgagggccc tgggcttggg gtgttctggt tttgagaacg gcagaccag gtcggagtga  
 1441 ggaagcttcc acctccatcc tgactaggcc tgcaccta aa ctgggcccct cctccctccc  
 1501 ttggtcatgg gatttgcctg cctctttgcc ccagagctga agagctatag gcaactggtg  
 1561 ggatggccca ggaggtgctg gagctaggtc tccagggtgg cctggttccc aggcagcagg  
 1621 tgggaaccct gggcctggat gtgaggggcg gtcaggaagg ggtacaggtg ggttccctca  
 1681 tctggagtcc cccctcaata aagcaaggtc tggacctgca aaaaaaaaaa aaaaaaaaaa  
 1741 aaaaaaaaaa aaaaa

## SEQ ID NO:3

25 atgcta cacacaaccc agctgtacca gcatgtgcca  
 61 gagacaccct ggccaatcgt gtactcgccg cgctacaaca tcaccttcat gggcctggag  
 121 aagctgcatc cctttgatgc cggaaaatgg ggcaaagtga tcaatttcct aaaagaagag  
 181 aagcttctgt ctgacagcat gctggtggag gcgcgggagg cctcggagga ggacctgctg  
 241 gtggtgcaca cgaggcgcta tcttaatgag ctcaagtggc cctttgctgt tgctaccatc  
 301 acagaaatcc ccccggttat ctctctccc aacttccttg tgcagaggaa ggtgctgagg  
 361 ccccttcgga ccagacagg aggaaccata atggcgggga agctggctgt ggagcgaggc  
 421 tgggccatca acgtgggggg tggttccac cactgctcca gcgaccgtgg cgggggcttc  
 481 tgtgcctatg cggacatcac gctcgccatc aagtttctgt ttgagcgtgt ggagggcatc  
 541 tccagggcta ccatcattga tcttgatgcc catcagggca atgggcatga gcgagacttc  
 601 atggacgaca agcgtgtgta catcatggat gtctacaacc gccacatcta cccaggggac  
 661 cgctttgcca agcaggccat caggcggaag gtggagctgg agtggggcac agaggatgat

721 gagtacctgg ataaggtgga gaggaacatc aagaaatccc tccaggagca cctgccccgac  
781 gtgggtggat acaatgcagg caccgacatc ctcgaggggg accgccttgg ggggctgtcc  
841 atcagcccag cgggcatcgt gaagcgggat gagctggtgt tccggatggt ccgtggccgc  
901 cgggtgcccc tcttatgtgt gacctcaggg gggtagcaga agcgacagc ccgcatcatt  
961 gctgactcca tacttaatct gtttgacctg gggctcattg ggctgagtc acccagcgtc  
1021 tccgcacaga actcagacac accgctgctt cccctgcag tgccctga

SEQ ID NO: 4

ctacacacaa cccagctgta ccagcatgtg ccagagacac gctggccaat cgtgtactcg 17663325  
ccgcgctaca acatcacctt catgggcctg gagaagctgc atccctttga tgccggaaaa 17663265  
tggggcaaaag tgatcaattt cctaaaaggt atggaagggt ccccttggac tctcatctgc 17663205  
ttcttccaac ccacctgtcc tctcgtcct catcccaac ataagcctca ggctctctcc 17663145  
catcttcagt ttcagccctc ggatggcctt ccacctatgc ttcgccccaa aatgattttt 17663085  
ccaacacaga ctctaataca cgatatgatg tccctgactc agactctccc tggtcccca 17663025  
tctgtggggc ctaagtcctg cctctgcccc agaggcctag tggaaaggta gctgattact 17662965  
gatgggcaca ggggaaggta agcttgagg agtccatttc ctaagggttc gagagtcagg 17662905  
aggtagagca cctccaccgc acctctcttg attacagatg ggggaaattg tgcctagaa 17662845  
tgattaggaa acatgtgcac ccaattccag tccagtcctc acagcagccc tcggggtagg 17662785  
caccacaatc gcagcagagg ctccaggagct cactgtaacc tccgccttcc aggttcaaac 17662725  
aatttttctg cctcagcctc ccaagtagct ggaattacag gcgtgagcca ccacaccg 17662665  
ccctgatttc ttaatatggc actcattata agattgtaaa agcccacctg tagaccgaac 17662605  
tgggcacact ggctgcctgc ttgtgacctc ttccaggga aggacacagc tccattagt 17662545  
ggctgaagta acacagttac aagaggcgga gttgggtttg gaactcagag ctccaggcgc 17662485  
cctaccttta gggctcatcc ccttgagcaa aatgatgctt cgaagagcat atcgttttaa 17662425  
ctgtgggttg taatcaaggg gcctgattta ggtgggaaat tcacttaaac ttgttttaaa 17662365  
aggaaacatt atgtcatcaa aatgggaaaa ggcagtttca cttgccataa ataggctatg 17662305  
gtaaaaaagt aaatgcaatg aaaacaacag tataattcaa tccaggctgg ttactattgc 17662245  
ctgcaggctg tgagactgat tagtgggttg aacggaagat gagcaaaagca caggcagggtg 17662185  
ttgcgaggcc atgccacact gagcctcctg taatatcatc agaaggtgga gggaggccgg 17662125  
gcgcagtggtc tctgtcctgt aatcccagca ctctgggagg ccaaggctag gagaacactt 17662065  
gaggccggga gtttgagacc agcttgggca acatagcaag atcctgtctc tacaaaaata 17662005  
aaataaaaaa cttagctggg ggtggtggta tgcacctata gtcctagcta cttgaaatgc 17661945  
tgaggcagga ggatcacttg agcccagaag ttcgagggtg cagtgaagta tggttgtgcc 17661885  
actgcactcc agcctgggct acagagcaag acctgtctt gcatttattt atttgttat 17661825  
ttatttattg agacagggtc tctctccat caccaggtc agagtgcagt ggcggaatca 17661765  
aggctcattg ccacctcaac ctccctggct taagtgtacc tcccacctca tgtttttgat 17661705  
atttttaga gatgcggtct cactatgttg tctagctgg tcttgaaactc ctgggctcaa 17661645  
gcaatccacc tgcctcaacc tcccaaagtg ctgggattac aggcgtgaac caccacacct 17661585  
ggccaagacc ctgtctcttt aaatgaatta aaaaaaaaaa aaggcgggg ggaagggtgga 17661525  
gggggaattc ctaagaagag tttttctcac tctgagggtc aacatccctg acccttgtgc 17661465  
cacctgctcc tgaaggttgt ctgacacacc tgagctctcc ttgtgactat cagtggcttg 17661405  
ggaaacatgg ggattgtctg gtgtacgatg ttcattgtct cctggccaga gggactggcc 17661345  
actgtccaca gtggctgggg aggtacccc ttctcagaag gcccaacagc cagcagtgc 17661285  
tacctacccc tggggcaggg gctgccacag gccaaagtct cagcctgtgg gaggtctgg 17661225  
ggctggccct ggccctgagg tcagtgggga agcaggatgc tccctctgtg gtttcagaag 17661165  
agaagcttct gtctgacagc atgctggtg aggcgcggga ggccctggag gaggacctgc 17661105  
tgggtggtgca cagcaggcgc tatcttaatg agctcaagg acaggatgtc gggcctgggg 17661045  
ggctgcgggc ctggggcagg gggctgctgg ccaggagtgg ccaggaggcag gaggtgactc 17660985  
agcctgggga agccaagtct cacagggcac ccattcatgt ccctagtgtt ggaggacat 17660925  
gggagtctgt ggtccccaag agaaggagag aggtcataaa aaggcagacc tcagtttggg 17660865  
ccaggccact ctgagggtgg tgcctcccc ttctccagg cgatgaaag ccttcataga 17660805  
attttaggct tctacattat gactttcaag ctgtgctctg tctatatttg tttgtttgtt 17660745  
cagcccctgt cctccaacca tacatagctc ttctactttg gtctattttg tttgtttgtt 17660685  
tgttcatttt tttgttgggt tttgttcttg aaatggagtc tcaactctgt gccaggctg 17660625  
gagtgcagt atgtgatctc ggctcattgc aacctccgc ttccgggttc aagcaattat 17660565  
cctgtctcac cctcctgagt gagtagctag gattacagg gcgtgccacc atgcctggct 17660505  
aatttttttt gtattttagt agagatgtgg tttcgccgtg ttggccaagc tgggtctgaa 17660445  
ctcctgaact caggctcatc gccacacctg gcctcccaaa gtgctgggggt tacaggcgtg 17660385

agccaccgca	cccaccctat	tttttatatt	gggctgaagt	ttaagactct	ggtctaagta	17660325
cttctgctga	agttttggtg	aaaattggtg	gtctaaaaac	taatttgaaa	ccctcagggc	17660265
tcagcagaga	agagaaaaca	gtgggagggc	cgggtgtaga	gtctgagggt	aactcctgcc	17660205
ccttcccaag	gggcggtcc	tcagctccac	tgtgggccc	gcatggccag	agcacctggt	17660145
cttcaaagag	aagccaggaa	tccagattat	taagtgcac	ttcctgattt	tttttttgag	17660085
actgagctct	gctcttggtg	agcaggctga	agtgcagtg	cacgatctca	gctcactgta	17660025
acctccgcct	cccgggttca	aacaattttt	ctgcctcagc	ctccgaagta	gctggaatta	17659965
taggggtgag	ccaccacacc	cggccctgat	ttcttaatgt	ggcactcatt	ataagattgt	17659905
aaaagccac	ctgtagacca	aactgggcac	actggctgcc	tgcttgtag	ctctttccag	17659845
agaaggacac	agctcctatt	agtggctgaa	gttctgagg	ctgaggcatt	cagttcagtg	17659785
ctctttgtag	gaacagaggg	gaggttgagg	cgggggcttg	cattggaatc	tggtagtgc	17659725
agcctgcctt	ggtgggggtg	gggtcaggga	tgccctcaggt	tatctgcccc	aagagtgtgg	17659665
gagccctgac	cccaggctc	cctggctgag	ctcaccttag	actcagagcc	acagtggatg	17659605
cctgaggcca	gcaggccctt	ctgctccaca	ggtggaaaag	cctagggtcca	gaaagaggct	17659545
gtgctcaagg	tcacctggga	agtggcccg	gccttgggga	gacccctggc	aggtcatcca	17659485
gtccagctct	ctagggtccc	agtcagggtc	gctgcctccc	tgctcccca	ccgcagcctg	17659425
agggtgtgaga	attctagata	gggccacgac	agtgtgagca	catgaaagat	taccaggaag	17659365
agggttgaaac	ctggctcctg	ggagagagag	gggtgtgag	ccttggcagg	aagccagtg	17659305
cttggctgcc	ctgggttcc	ggggccagg	catgcgtggt	cacagtccac	agcctagggc	17659245
tgggccaagga	ggacatgcct	gccagagtcc	cgagggtgag	gggaaggaag	ggacaggagg	17659185
cgctcagctg	gggcaggagg	aaacccaaac	agaatggtgt	gattgaacca	ggctgggggt	17659125
ggggggccta	ggttccagg	ccccacccat	ttgagggg	ttcaggggaa	ctgtgttggg	17659065
ggctggcctt	ggctggcctt	ggctggcctt	ggctggcctt	ggctggcctt	ggctggcctt	17659005
taataataca	aaatagctgg	gtgtagtggc	atgcacttgt	agtcctagct	acttgggagc	17658945
ctgaggcagg	agaccttgag	cccaggagtt	tgaagctgta	gtgagctatg	attgcaccac	17658885
tgactcctag	ctggatgac	agagtgcag	tgtctcttaa	aaaaaataat	aaaagtatta	17658825
acaggtagag	tcccaagtag	aaaactgagg	ttgagggtag	gaggagaatt	caggtatgtc	17658765
aaactacaaa	gttaaccaag	atggtgatcc	agctgcata	ttggcttggg	gctccctggc	17658705
agtcagaaca	aaaggagaaa	catgatggtt	tctacggcac	ctattaagat	gaagaagtag	17658645
gccgggtgca	gtgactcatg	cctgtaatcc	cagcactttg	ggagaacgag	gcgggcggat	17658585
cacttgaggt	cgggagtttg	agatcagcct	ggccaacatg	gagaaacctg	gtctctacta	17658525
aaactacaaa	attagccagg	catggtagt	catgcctgta	atcccagcta	cctgggaggc	17658465
tgaggcagga	aaatcacttg	aacctgggag	gtagaggttg	cagtgcagcg	agattgcg	17658405
attgcactcc	agcttgggca	ataagagtga	aactccatct	caaaaaaaaa	aaaaaaaaaa	17658345
aaagaaaaag	atgaagaagt	agtcagtcac	tcaacacatc	tgtattgaat	gccaactgta	17658285
catagagaat	aagacagcag	ggctctctgc	cacctgggat	ttgcatttga	gtcgtggaag	17658225
attaaaatta	aggaagcaac	caccacaag	catcttagag	agcaccagg	gctatgaaga	17658165
aagtgaaaaa	tagagggtaa	ttggatggtc	agggaggggc	tcacagagga	ggtagatgtt	17658105
gagttgagac	taaacaagg	agcaggtgat	actcatgtag	aggtgttttt	tttttttttt	17658045
tttttttttg	gagaaggaat	ctcgctttgt	tgcccaggct	cgagtacagt	ggtagcagct	17657985
cagctcacag	caacctctgc	ctcttggttc	aagcgattct	cctgcctcag	cctcccaagt	17657925
agctaggatt	acaggcacct	gccaccatgc	cgggctatct	tttgtatttt	tagtagagac	17657865
ggagttttca	ccatgttggtc	caggctggtc	tcgaactcct	gacctcaagc	aatccatctg	17657805
cctcgccctc	ccaaagtgtc	gggattacag	gcatgagcca	ctgctcctgg	ccctcatgta	17657745
tagctttgaa	ggaagaatgt	ttcagaatcc	caggcctgga	gggtggagg	gacttgatct	17657685
tccaaagggg	agaagaatgc	ttgggaggcc	ggatggaagg	gaataaaaa	ttgtggctcg	17657625
tacacggtgc	agttaggggg	gccagagccc	caggccacac	aaggctcttg	aggccgtggg	17657565
aggagtgtat	atgttggttc	agggaccttg	gacagtcacg	aggggggttt	cagcaggagg	17657505
gtgatatggt	gtgacatgcc	cttgctgccc	aggtgggacc	caagcccgtt	tcagacatca	17657445
tctggcacct	aaggctgcag	ctcaggaaca	tctcccacct	ccctgcagat	gtctgcaatg	17657385
ttctttttct	ccttctctctg	ctgtgggcgc	ccagagagtg	ccctagagag	tccttcagg	17657325
ttctcaggct	gcttttccct	ggtcattctg	tgtgtgctgt	gtaacatcca	ccgtctcccc	17657265
tgctcatccc	cattctaccc	ccaacccctg	cctggggctc	atgcctgact	ctgcactgg	17657205
gtggcctttg	atacttaata	aacagggcac	tgaaggagaa	gcaggagctg	gacgtttgca	17657145
agatgtcaat	tcagggaac	ccatgtttat	caagctcctg	ctgtgtgcaa	gggtccagggt	17657085
tggccctctc	gagggtagct	gttgagctcc	ccagtgcctc	agcactgggc	tcttgccctt	17657025
gggtgattct	cgggtgacag	tttgccatgg	agtgtcggtt	agtgtgagg	agcatctgac	17656965
atcctgcccc	tgtgactct	gcactggaca	gtgctcagaa	cacgtggatc	cagcaagctg	17656905
tcagagggca	ccactctgtg	atctagggtc	tgaggggatg	ggatggagca	aaagaccaca	17656845
tcccttttct	gctggagctg	gcatttaggt	gggagagctc	gacaataaat	gtaataatta	17656785
agtaatgaga	taatatgtta	gatgggtgctg	agtgtcgtga	agaaaggaag	ggacagcaga	17656725
aaaggggtgg	ggagagctgg	tgagaggatg	gcagttttaa	atcaggagtc	aggaaagggc	17656665

ttactacctg	tgatcacagg	tgacatgtgg	gaagggagtg	agggagtg	tgatgtgggc	17656605
atctggggaa	gggcattcca	agcagaagaa	acagcaagtg	caaagatccc	agggcagaac	17656545
tatctgtcat	gagttccagt	atagtggtga	gagaaggaga	cacagaccat	agctccatgg	17656485
agcacctgga	gggaccctgg	agagtctcta	ggggagtgag	ctcctcttgg	tctccaactc	17656425
tctcttctct	tccttgaggg	gctcctctct	cctttaaaaa	aaaatttttt	ttaattgtgg	17656365
taaaattttac	ataacaaaat	tcgccattaa	ccactttaaa	ctgtacagtt	cagtgccctt	17656305
tagtccattc	acaaagtgtc	gcaaccatca	tctctagttc	caaacatttt	catcactcca	17656245
aaaggaaaacc	ctgtgtcctt	taaacacttg	ctccccattt	atccccccaa	gtccccctgg	17656185
taatcactca	cctgcattct	ctctctatgg	atttgcctat	cctggatatt	tcataataat	17656125
ggaatcatac	aatatgtgac	cttttgtgtc	tggtctatct	cactaagcac	agcgttttca	17656065
acattcatct	gtgttgtgtt	gtagcatgta	tcagtacttc	attccttttc	acagcagaat	17656005
gatattccat	tgtaaaacac	tacatttttt	ttatccattc	attagtttat	aggccttttg	17655945
gctattgtga	gtagtgttgc	tgtggacatg	tgcatacgag	tatttattag	aatacctgtt	17655885
ttcagttatt	tggggatatac	acctaggagt	agaattactg	ggtcacatgg	taattctgtt	17655825
taattttctg	aagaaccatc	aaggtgatct	ccacgggggc	tgcaaccattt	ccaccagtaa	17655765
tgtaccaggg	tcccaatttc	tctacatcct	tttcaatgct	tgttattttc	tggtgttttt	17655705
ttttttcccc	cccagtgtgg	ccatcttact	ggatgtgaag	tggtatctca	tggttttaat	17655645
ttgcattttac	ctaattggcta	attaacactg	aggatctttt	catgtgctga	ttggcttatt	17655585
gtatatgtca	tttggagaaa	tggttattca	agtcctttgt	ccatttttaa	aattggcctg	17655525
tctttttgtt	gagttgtagg	gttctttata	tattctggat	attatttaat	ttgtaaataa	17655465
ctcctccccat	tctgtgggtt	gtcctttttt	tgatagtgtc	ctttgatgca	caaaaatttt	17655405
agttttgtct	aagttccaatt	tatctttttt	tccttttctt	taggtgtcat	atctaagaat	17655345
ccatttggcaa	acccaaggtc	atgaagggtt	accgcatgtg	ttttcttcta	agagttttat	17655285
agttttcact	tatatattagg	ccttgataaaa	ttttgagtta	atttttgtat	atgtgtgagg	17655225
caagtccaac	ttcattgttt	tgtactcaga	tatccagtta	tcccagcacc	atttgttagg	17655165
ctgtttttcc	cctgttgaat	gggtcttggt	cctttgtaga	aaatcaactg	gccatagatg	17655105
tatggatttta	tttctagact	ctcaattcta	ttcatttttt	tggtttgttt	gtttaagaaa	17655045
gggttgcatt	ctttcgacag	cccaggctgg	agtacgggtg	ctccatcttg	gctcactgca	17654985
acctcgtct	cctgggttca	agcaattctc	ccatctcagc	ctcccaggta	gctgggacta	17654925
caggcgtgtg	ctaccatgcc	tggctaattt	ttgtgtttct	tggttagagat	ggggtttcac	17654865
catgttggct	aggctggctc	tgaattcgtg	acctcaagtg	atttgcctac	ctcggcctct	17654805
caaagtactg	ggattacagg	catgtgtgag	ccactgcgcc	cagccaattc	tattcatttg	17654745
atctatatgt	caataccaca	ctatttttgt	actgttactg	tggttactg	tggttattgt	17654685
ggctttggag	caaattttga	aattccagat	tgtgaggcct	ccaactttgt	tctttttttt	17654625
tttttgagac	gcagtctcgc	tttgtcgcct	atgctggagt	gcaatggcgc	gatctcggct	17654565
cactgcaacc	tccgccttct	ggtttcagg	gattctcctg	cctcagcctc	ccgagtagct	17654505
gggattacag	gcgcccgga	ccacgcctag	ctaatttttc	tatttttagt	agagatgagg	17654445
tctcaccatg	ttggtcagg	tggtctcaaa	ctcctgacct	catgatctgc	ctgcctctgc	17654385
ctcccaaagt	gctgggatta	caggcatgag	ccaccgtgcc	cagccaactt	tggtcttttt	17654325
taagatcgtt	ttggctgttt	gaggtccctt	gagattccat	gtgaattata	gcatcaactt	17654265
ccattttttg	caaaaaaggc	cattgggatt	ttgacaggaa	ttgcattgag	taaattgctt	17654205
tggggagttt	tgccatctta	acaatattcg	gtctttcaat	ccatgaacat	gggatgtctt	17654145
tccgtttatt	tgtctcttta	atttctttca	gcaatgtttt	gtagctttca	atggacaaat	17654085
cttgcacctc	ttggttaaat	ctattcccat	gcattttatt	cttttcgatg	ttattataaa	17654025
tgaaattgtt	tgaatttcct	tttaagattg	ttcattgctg	gtatatacaa	taatcagttg	17653965
tatagaaata	caactgattt	ttttgtgttg	atcttgtatc	ctacaacttt	gctgaatttg	17653905
tttttagaca	tttttttctt	tttttttttt	tttttttttt	tttttagacag	agtcctctct	17653845
tgttaccagg	ctggagtgc	gtggcatgat	ctcggctcac	tgcaacctcc	gcctcccagg	17653785
ttcaagcgat	ttttctgcct	cagcctccca	agtagctggg	actgcagggtg	catgccacca	17653725
tgcccagcta	atttttgtat	tttttagtaga	gatgggggtt	cgccatgttg	gccagtgtgg	17653665
tctcgatctc	ttgacctcgt	gatctgcccc	cctcggcctc	tcaaagtgtc	gggtattacag	17653605
gcatgagcca	ctgcgcctgg	cctgtttctt	agctttaata	gttgtgtgtg	tgtgtgtgtg	17653545
tgtgtgtgtg	tgtgtgtgtg	tgtgtgtatt	ctttaggatc	ctctatata	aacatcatc	17653485
cgtctgtgaa	gagaggtagc	ttcctttcca	atttggatgg	cttttattta	tttttcttgc	17653425
ctaattcctc	tgattggaac	ttccagtact	atgttaaaata	gcagtgtgtg	agcaggcatc	17653365
tttgtcttgt	tctctgatctt	agacagaggg	ctttcaatat	tttaccattg	agtataatgt	17653305
cagctgtggg	gttaaatgtt	ttaacgcctt	tctatcattt	gagggagttc	ccttctgttc	17653245
ctagtttgtt	gagtgatttt	atcacaaaag	gtatttgaat	tttgtcaaa	gctttttgtg	17653185
catcaactga	gagatcgtgt	tttccccctc	tctgcttttg	ctccccctct	actggtagaa	17653125
aggaccacc	taaagcaagc	agtgggcgcc	ctagaggggt	tacagcctag	ctcttccttg	17653065
agagcagttc	ttggtttgaa	cctgagggca	gcgggtccgc	ctgaggaaac	caggtgtctg	17653005
gaaggtgaag	gcttgtggag	ctgagtagat	ggggcagtag	gtcccagaga	tatggccagc	17652945

cccagtcattg	tectgctctc	tgtggagttcc	cacagaggct	gacgaggat	gggggcccctg	17652885
atagctggct	acatgcaggc	catgcccttt	ggcgggtgg	ggcgtcagtc	tggggcagac	17652825
ctcccatgct	cacatagtg	gtcattcac	ccagcactgc	cttaggttgg	gtcccctaga	17652765
atgggtggctc	ttaaacccca	gcaagtatct	gaaacactgg	agggcttgtt	ccagcagatg	17652705
gctgggcccc	tcccagagtt	tctgatccat	gttgtcttgg	gtagagactg	ggaatctgca	17652645
tttctaatac	attctcaagt	gttgtggatg	ctgctggtct	gagaaccaca	tccttagaag	17652585
cagagtctga	gatggtgcag	gcatgttcag	atgaacctg	caagaggcac	aggcagtggtg	17652525
gagcgggcag	agtgaagcag	tgagcacaga	tgtggatttg	gaagtgtggc	ctcagcctga	17652465
ttccatggag	atctctgggg	cgtgaatgtc	accacagggt	tgccctgccc	agaagcatgt	17652405
ggcctggctg	ttacaggccc	ttgtcagtc	tggtctctct	gggatgatgc	agggtgaggtg	17652345
gcttctgtca	ggagaagggc	tctggtgcac	cagccagaaa	aggggatcaa	cgccatgcat	17652285
ggccagcacc	tactgtgtgc	caggcatggc	ctcagcactg	tctgcacagc	agtgaagcaga	17652225
cgcgtgctgt	cctcctggag	ctggcatcct	tttgaggag	atagatgcta	atcgggacag	17652165
tctgtagcct	cagggagaga	agtgtatct	gggaagatga	agccaagggtg	tgggctccag	17652105
ggggccccag	gtgggagtat	tttattttat	ttttttgaga	cagagtttca	ctctgtcacc	17652045
caggctggag	tgagtggtg	cgatcttggc	tcactgcaac	ctccaccctt	tgggttgaag	17651985
agattctcct	ccctcgctc	ctgagttagt	gggattacag	gcacctgcca	ccatgcccgg	17651925
ctaatttttg	tggttttaat	ggacaccaga	tttcaccatg	ttggccaggc	tggtcgtgaa	17651865
ctctggacct	caagtaatcc	gcctacctca	gcctcccaaa	gttctgggat	tacagatgta	17651805
agccaccaag	cctggctggg	tgtggggatt	ttagattaga	tgaggaggac	aggcctctct	17651745
gactggtttc	cacctctaag	tcctcatcca	aagccttgtt	ttatagatga	gacagaggca	17651685
cagagaagtg	aattctaaat	tcacatagcc	agtggcagaa	cccagacttg	gaccagtttg	17651625
gggaacttct	gagcctgtcc	accccagtc	tagcctcacc	cacagtgcct	tgcccagggt	17651565
cgagactatc	agggagcctg	acctgctgga	tctgggcagt	cccaccgtgg	catgctgcat	17651505
gtcccagaga	aggtatctgt	cagcagtgca	gcacccccca	cctgccccac	ccacagctcc	17651445
ctcgggggct	atccctggaa	gtgttggtca	gaaagtgaat	ctccagatgt	cacctgggtg	17651385
tgccctgagc	tcctcctacc	tgccacctcc	tctgaccaca	tagagcctgc	tctagcccg	17651325
gcccctcttc	ctctcctccc	ctcaccagg	gaccgcacac	tagtccgccc	caccacctct	17651265
gtttattttct	caccttgccc	actgatgggt	ggtttctcct	agagcgggtc	tgccctgtgg	17651205
aaccttctgc	aatgatggaa	atgctcagac	ctgctctgtg	cagtccagtc	gccactggcc	17651145
gcatgtggct	cttgaaatat	ggagagtgt	actgaggaa	caaacttgaa	tttttaaaat	17651085
tttgatgaat	ttacaatcac	tcgtaagtag	ccacctgtgg	ctggcagcca	ctggattgga	17651025
tgggtcgtgt	ctagggtgtt	ggcaaccaca	tcactgcctt	gtgcagaaac	cactgctgca	17650965
ccaggagaag	gcccgaagtgc	cagcctctc	ttcactgccc	gaagcctgct	gctccgctga	17650905
ggggctcgtc	tcgccaacgt	tgccacagca	aacacacata	ctttctcctg	tgggggctgg	17650845
tcctgtcggc	caagtcccgt	gcatgtcct	gggtggctgc	acctggcccc	tgccaccagg	17650785
caggccaat	ctgtggagga	taccaaggaa	cctcttttag	gttcccaagt	gtgtcccag	17650725
ccactgcagt	gttgagaag	gttagtgtgt	gtgacttaaa	aggcaaaag	ggcaggcaga	17650665
tcttctgaca	tctgggggga	gcaaagttag	aatggaatat	ttgctgcaga	acttctcaga	17650605
gccttttagca	tgctaggatg	tgctgcaaat	ctccaggagg	caggcggcat	aagccatgct	17650545
tcccaaaccga	cttgccggtg	gaagcctcct	tgaggagtgc	tggtgcgagac	ccgtggctgt	17650485
ggagcacacg	agagaatgcc	tttctcgtgg	tttgtgtcca	tgctgggctc	tcggctgcat	17650425
tgcttctccg	tctgtgtccc	ctgctggctt	cccagtgagg	gagggaggct	gtgactccat	17650365
gtgctccttc	agcggctcgt	ttgtttgtct	attcgttcat	ggaaaaccat	ggttccatgc	17650305
cagccacacg	cggggcctct	gccgggcagt	gggatgagtg	tggtgaacaa	gaggagctga	17650245
tgacctcagg	cagggacctt	cctttctctg	ggtctgtccc	gcaacataca	cacacgcaca	17650185
cacgcacacg	gacataacctg	tgacacacat	tatacacaga	acacatacac	acacatacat	17650125
acactcatgg	gtgtgtcctg	cagctgtctg	ctgtgtctgg	tcctcagctct	tacactccca	17650065
ccccttccca	ggccctgtga	tgccctccatg	ttaccggccag	agggcctggg	cttgtggaag	17650005
tgggtgccccg	tgggcacctc	tccttcccga	ccatgagtgg	gaccctgtct	actgccttct	17649945
ctaccagagt	gagggagtga	tgccagcttc	ccccgccttc	agccgcccctt	gccggcctgg	17649885
gctgggtggcc	atgggcatte	cccagcagtg	tgggcaggct	gggtgectgg	cacccccagg	17649825
actatgacag	aagcctcccc	tgttgggccag	ggcctaagcc	atgaggcccc	tgctggggcc	17649765
tgacttaggg	tgtgtcctgc	cttttgtccg	gccctgagtg	gcctggctac	agcacctctt	17649705
ggccctctga	ggttcgtcac	ccctctgcca	tcacacccat	ccctggccac	cctctccctg	17649645
cctgtctgct	gctgtctgtc	attgaacatg	ctcgtgtttc	tcccatccta	aaactcctcc	17649585
tcctgggttg	tgaacgcaat	ggccacactt	cccactttcc	tctcatggaa	tgtctgcagc	17649525
ttggtgctc	cctccacctg	ctccttcag	ccacctctc	tccacctggc	ctcctgagca	17649465
ctgcacctta	ggtctttcca	catctcacc	tgtcccagg	aagcccttga	tcgtccccag	17649405
gggttctctc	tctgggctt	gcccttcagc	atgggaagcc	tgagtcacca	accagccct	17649345
tcacctccca	ctctccacc	cctgttctga	gctccagct	cacttaaac	tcagctgtct	17649285
cacctggctg	ccccagggc	tgacttggtc	catagagagc	agaacctagt	gccgcctctg	17649225



taccctgctt	caggttcacc	tccaagtgcc	attaccctca	caggccccag	acccgacacc	17649165
tgggcccctc	accccttgte	cctgcatgct	gcctgcta	acctgctcct	cttaccaccc	17649105
cagacccttc	ttatctcatg	cttccctctc	aggctgcta	cttctctatt	cctgttcccc	17649045
taattgggtc	tccttgctgc	agctagtgc	gcttgggaca	gcaccatcta	tggttcccta	17648985
ctgccctgac	gacaatgtgt	gagcctgtgc	taggagacca	ggccctgtgt	gataagctca	17648925
gcctgcccctg	ttccagctgc	acccaccttc	tctagatcat	ggactcactt	ctctgcccac	17648865
agataccttt	ttcccttgac	ctctgcatct	ggataactcc	tattcactct	tcacctcctg	17648805
caaatgccat	cacccccaga	aagcctctct	aataaccccc	acccagttct	cctcttcata	17648745
accacactca	tcacactgca	aataagtgtc	tgcaagtgtc	ctggcatgag	aatgggccc	17648685
ccagtgccca	cctggggcac	ctagcaggca	cttagtaa	atttacaag	tgagtggctc	17648625
tgcctcgctg	gggtggggag	cagggatg	ttttcagcca	ggagatggct	tggggtttgg	17648565
gttcagctgg	gcagccagtg	ccatggatat	ttacctgggtg	cacttggagg	tcacagggca	17648505
cactctgtcc	tgatcttagt	gcagatacct	ttcaggtagc	gtagaccccc	ccagcctcag	17648445
cagctggaga	tgagggcagt	gcataccctt	tgccagggaag	gtccgattcc	caatggacaa	17648385
agaggcaatg	cagtgcgagg	gagccagagg	ccagggtccc	cgtcccagct	ctgtcagtga	17648325
ctcattgtgt	ggccttggga	agatcctcgc	tgcctaggcc	tcagtgtccc	cttctgtaca	17648265
gtgggtggct	tagactaatt	tgttatccca	agcagtcct	agacctgcac	tgctgacttg	17648205
gagccctctg	cacctcctgt	tctgggcaca	agagggcagc	caagggcctc	agaacgtga	17648145
ggaaccctgg	ccaactagct	ttaagaaatg	catttgttaa	actgctcttt	actgagccca	17648085
gagcttgcca	ggagcctgg	agggttgtgg	ctctggctct	catttctacc	aaaggaagt	17648025
tgcttgacca	gggagttcat	ccaagggcac	ctggaaactg	tcctcaaggc	atttcccggg	17647965
gaaccaattt	ctcacgggtt	gcctcagggt	ggggaagcgg	aggccaacag	cccctgtctt	17647905
tttccgagct	gttcccttgc	tgttgctacc	atcacagaaa	tccccccgt	tatcttctc	17647845
cccaacttcc	ttgtgcagag	gaagggtgctg	aggcccttcc	ggaccagac	aggaggaacc	17647785
ataatggtag	gtgggtggg	ggggcatggc	tgggtgggg	gccccacac	cccagggtcc	17647725
ttctcacctc	ctttgccttg	gaatgccctc	ctcccactta	gtagttgaac	agaatcctaa	17647665
atattctcta	aggctcggca	acaatgacct	tttctccaaa	agcctttttt	ccccactttg	17647605
ggacatcaga	attctcttct	catcgttcct	tctctatga	cctcctattt	gttaccgtaa	17647545
ttgctagtat	ataatatacc	tctccacca	ccaaagcgga	tatcctagca	ctatggcttt	17647485
aaggcacacc	ccctcaccag	ttttttcttt	ctttcttct	ttttttttt	tgagttagag	17647425
ctcgttctgt	cgcccaggct	ggagtgcagt	ggtgtgatct	tggctcactg	caacctctgc	17647365
ctcctaggtt	caagegatcc	tcttgctca	ggctcctgag	tagctgggac	tacaggtgtt	17647305
cgccaccatg	cctggcta	ttttgtattt	ttagttaga	cggggtttta	ccatgttggc	17647245
caggctgggtc	ttgaactcct	gacctcaaat	gatccactca	ccttggcctc	ccaaagtact	17647185
gggattacag	gctttgagcc	accatgcccc	gcccta	acccaaaatt	aagatggaga	17647125
actgatectc	catgacttca	gtgatgaata	agcctccacg	tctccccac	tgcggtgtg	17647065
gcaacaaga	atccccacag	caaaattagg	tttcacatg	tgtgtgtggt	tttttttaaa	17647005
aaatgtgcca	cacactgcct	agttatttgg	agatagagga	atgtttcaca	tgcaaatgta	17646945
tgaggatcta	acccagccct	ggatcactac	ctactgatcc	cctacagtcc	tgttatgttt	17646885
gtaaatttgt	actttttcct	ttagcttagt	agaatattac	tgcccatccc	caaaactatg	17646825
atttctctgga	agatttctagt	atttagtcta	ctatatttct	ttttttgctt	tttttttttt	17646765
tttttttagg	acagagtctc	actctgtcct	ccaggctgga	gtgcaggggt	gtgacctggg	17646705
ctcactgcaa	ccctctgcctc	ctgggttcaa	gtgatcttcc	tgcctcagcc	tcccagtag	17646645
ctgggattac	aggcacacgc	cactctgcct	ggctaatttt	tgtattttta	gtagagacgg	17646585
ggtttcacca	tgttgccgag	gctggctctg	aactcctgac	ctcaagtgat	ccgcctgcct	17646525
cggcctccca	aagtgcctggg	attacaggcg	tgagccactg	cgcctggccc	agtctactgt	17646465
atttctgtga	gcaaaacttt	gcctattttc	cctttgaaag	ccatatcaaa	attattgtca	17646405
gctcatatgt	gatggatgat	aagtactttt	attttttcca	gtttccttgc	acaatttcaa	17646345
agggtgcttat	gcactgtaca	tctcatatgc	cagccaagct	ggcacttact	tcctggactg	17646285
ttgcttgggg	tagggagttc	cttctatacc	cctgccttgt	agctcagctc	atccttcccc	17646225
cagagctggc	tgaagcagt	gtttatggaa	tgagtgcagt	aatcagtga	tgaatgactg	17646165
gtggatcgcc	tgccctgcgc	ccctcaccct	ctgctgtctc	ccaaaggcgg	ggaagctggc	17646105
tgtggagcga	ggctgggcca	tcaacgtggg	tgagtgctgg	gaatgtctc	gggaatgtcc	17646045
agcccgctt	gggtggaactg	gcctgaaagg	gggctggggg	aggcggggag	gatcctggag	17645985
gtggcagctg	tgaattcaga	agctctgggt	ttcccagtc	accctagcct	ccttgtggag	17645925
tggcctggag	gttgatgtgt	agcctcctag	gtacctggga	gagactgacc	agtgcctcca	17645865
tctgacgtgg	gacattgtgc	taaggaggtc	ccgggtggt	tcccagccc	cctcttgcg	17645805
tacttcgggt	ggcaggggagc	ttcctccct	ccagagagcg	tgtgccatcc	ttgggagct	17645745
cagcatggtc	tgaagcctgc	cttgtgtctt	ccctgaagg	ctccacctgt	gtcctggggc	17645685
ccaggacagc	ccacagaggc	ttggtcatgt	tgggttgggt	gggcacatcc	tgggtcaata	17645625
ccaccacctt	ctcaagggtc	cagagggccc	gtgctcccca	gcccccttga	atctcccaca	17645565
agattggctc	atgggagggc	tgcacgggag	tctcccttgt	ccctgtcatt	gtccctcctg	17645505

gaggcacagc	acttgacaat	ttacaaagct	ctttttcacc	aggctctttt	tttctttttc	17645445
gagacgtagt	ttcactcttg	ttgccccaggc	tggagtgcac	tggcgcgatc	tcggctcacc	17645385
gcaacctccg	cctcccagg	tcaaacaatt	ctcctgcctc	agcctcctga	gtagctgaga	17645325
ttacaggcat	gcaccacccat	gcccggctaa	ttttgtattt	ttagtagaga	cagggtttct	17645265
ccatgttggg	caggctgggt	cttgaactcc	cgacctcagg	tgatacgccc	acctcgctcg	17645205
gcctcccaaa	gtgctaagat	tacagacatg	agccaccacg	cccggccttc	acccagactc	17645145
ttatttgagc	tgggcataat	tgtcaggcct	gtctcactga	tgaggaaatg	gccatggaaa	17645085
gatgcgtact	ggatcgtgta	gagccctaaa	gcagggtccc	ccagcctttg	gctctgaact	17645025
ctgcagggga	gagtcacact	tgggccactg	cacagttgag	gggagcccca	ctctgcaggg	17644965
gctgggtctc	ttccatcttg	gtattaccag	gtgcctagca	ttcagtcctg	catagtaatg	17644905
atgttatggg	actctgctgc	acaaacccgg	gagtgatctg	tgccctgcgt	gtctacagca	17644845
gggttccgag	gagggcctgg	atggccctcc	ccatggcagg	tgttactgcc	tggtagagg	17644785
taagagcctg	gatcctgatc	caccctgggt	ttgatcctgg	ttctgccatt	acctggctgt	17644725
gtgaccctgg	gcaagttgct	gacctcctct	gtgggtcagt	ctcctcatct	gtaaaatggg	17644665
gatggtgatg	ctaagcccc	tcctcgggct	ggaggggagtc	ttcagcaagc	tcagttgctc	17644605
agtcaagggt	tcaactgtggc	tgtcttctca	tcattaggag	ccaacagtag	cctcctgggg	17644545
ggtgggagag	gcaagttcct	ggtatccatg	gggccagctg	cacactgtct	gacggagcag	17644485
ttgttgggct	caatttcaga	gggcctctgc	aattcaggcc	atcccagggg	ctgcagggga	17644425
gggggtatct	atggggcccta	gggctctgag	gctgtgtctc	agggttgagg	ggtgatggat	17644365
cccgggctct	agggccctcc	tcgtggctgt	aggcagtcac	gaccagcaga	gggtgcccct	17644305
cctgaccacc	cgctttggcc	actggcagaa	tccgtgtggc	ccccatacca	ccactccttc	17644245
ctggagtggg	gagccacatg	gagccaggcc	cagcttggtg	gggacaagga	gcagctttct	17644185
gcttctggaa	tgatgagcta	tctgttgctt	agggtgtgta	gtggcactga	ggacttgctg	17644125
gggacacctt	gaagatgtgg	ctgccttctg	gcctggggat	ggtgacatgc	cccagcactc	17644065
agcttagttt	gccaacccag	agtcggaggg	acagggttct	gagagctgag	cagggaggat	17644005
gctgggggag	gtgaagggat	ggaggagctc	ctggactgag	cctgggagcc	tggtctctgag	17643945
cagcacccgt	ctctgccctt	ccgcaggggg	tggtctccac	cactgtctca	gcgaccgtgg	17643885
cggggggcttc	tgtgcctatg	cggacatcac	gctcgccatc	aagggtgtgc	tatgagcaag	17643825
tgggtctcgc	cctccaagag	ccctcctgga	atctcccca	tagctccaaa	ttaactgttc	17643765
tcaccctgaa	ttatagacaa	ggggcctatg	ctggagcagg	gagggggctt	gtttgggttg	17643705
ctcagccagg	ctggaactga	atccagatct	gacacttgct	cctcttccat	gttgcttaga	17643645
agggttgctt	gtggtggaag	ggagttattc	cagcctccca	cagagccagg	ggactagaga	17643585
gggtcaggat	ctgctgtata	gccacatatt	aagtttaggg	aagaagggca	tggtctggcaa	17643525
agggagtagg	gagtggaaag	aatgatgtgt	ctgatagcac	ctggcagttc	tgcatgctcc	17643465
aacccgcgct	gtgctccagg	acttactccc	tgaatcctcg	cagacagaca	ggggcccaca	17643405
gaggtgaggg	catgcaaaata	gcaggggcag	aattggcgct	ggcctctggt	ctgtggggcc	17643345
ccacaactcc	cctgccactc	tgtgcctggc	cttgtgtctg	gcacagggaa	ctgactgacc	17643285
tgttcctatg	tgtgcctgct	ctcatggggc	acatgactg	atggggggaa	gcaggccatt	17643225
aggagaaggg	ggaagcacag	gagaccttcc	tggggaggag	ggaatgaagg	cttctctggaa	17643165
gagggggcat	ttaggacttg	gccttgtagg	ataaggcaga	ggttggggac	tgaagtccca	17643105
gggtctgtgg	gattctctcc	ttaaccctta	cacatttctc	agggaatctg	ggaaaatcca	17643045
gggctctagt	gacccactta	cctcctgacc	tatgacctt	cagggcacag	gacatgcccc	17642985
ctcctccagg	gagccttccc	tgaccacctc	acatggagcc	acatggagcc	ccacagctgg	17642925
agctgcacag	ctctccctgg	caagtgcac	ctttgtctgg	tggtctgatt	accacaagc	17642865
attaggcccc	cctcccgcgc	cctcgccagc	cagctgggag	ttgtctgagg	gctgggtcct	17642805
ctgtccgccc	cagatcctca	tgtctaccct	ctcctccctg	gcagtttctg	tttagcgtg	17642745
tggaggggcat	ctccagggtc	accatcattg	atcttgatgc	ccatcagggtg	agtgccttgc	17642685
aggggctgga	ctcttagggg	acctgccacc	ccagtttcca	gaatcttccc	ggggcaggag	17642625
agtctccctc	ctcatgtccc	cacggctctc	acggcttctg	tcttctgtct	ctcgggctac	17642565
aaatgcaggg	tctgtctttg	tactctgtgc	caggacagcg	ggtcctctc	attgctcccc	17642505
agggtcctcc	ctccctcctc	ctgactgccc	ccacatgagg	ctcttctga	agccactct	17642445
gatgggactg	ctctcggtg	cagagctctg	ctgtgggtcc	ccattgctta	tgaataattt	17642385
ggggcactgc	ccctgccc	gagctgctga	gcactggcca	cctgcccctc	aggcgagtg	17642325
ccacacacat	ggcttggtc	gggcacctgg	ggtcaccatt	taagaactcg	gcgcctagg	17642265
agtaaaagt	caagcagag	ggttacctcc	tcctcaggac	ccctaataag	gccagtgcct	17642205
ctggtcagac	agggagggga	cccagtgggc	tccggaaggc	acccccctgc	accattactg	17642145
ctgtggcttt	gtgctagtgg	gggcccctgc	tgtgggtctt	gcgaccccca	actcctgagc	17642085
caggtcacat	gtggacagtc	ctttacagtt	tgtctttcac	atccctgatc	ccaaccagtc	17642025
ccaccacaga	cttgagaggg	tggcagagcg	ggatttcttc	ctctgatagg	gaacctaaag	17641965
gcactgggct	tgtcaagcc	catgctagaa	ggtgtcgggg	cctgggttta	agggtgaatc	17641905
ccagctctgc	cccttaacag	tcatgagacc	tgtgcccccc	gagagcaggc	cgtgctgccc	17641845
tggcaaatgg	ggagtttctt	gaggggtggg	tgggtggcag	agccccagcc	ttgcctaggg	17641785

cacctaccg	agagcggcta	ctgtgacctc	cccacagggc	aatgggcatg	agcgagactt	17641725
catggacgac	aagcgtgtgt	acatcatgga	tgtctacaac	cgccacatct	acccagggga	17641665
ccgctttgcc	aagcgtaaagc	tgtgtccccct	accctcatct	tgggtgtgtc	cttgtggatg	17641605
aggctctctc	ctgagtgtct	cctgtctgct	aggccctgca	gaagccactg	cagtgggtca	17641545
tagcatccct	gtgaggatgat	cctttccatt	ttacagatga	ggaaaccgag	acctggagaa	17641485
gtcactcgac	ccaccaaga	tcacataacc	cttacaataa	acatgcattt	gtctggcaaa	17641425
aaacagggaaa	gaatgaaaga	aaaaaaagaa	aaataggata	aatttgaaaa	tacgaaataa	17641365
gaaataaatt	cacataggct	gggcgcggtg	gctcacgcct	gtaatcccag	cactttggga	17641305
ggctgaagtg	ggcggatcac	ctgaggctcg	gagtttgaga	ccagcctgac	caacatggag	17641245
aaacccccatc	tctactaaaa	atacaaaatt	agctggatgt	ggtggcgcat	gcctgtaatc	17641185
ccagctactc	gggaggctga	gacaggagaa	ttgcttgaac	ctgggaggcg	gaggtttcgg	17641125
taagccgaga	tcgcgccatt	gcactccagc	ttgggcaaca	agagcgaaac	tccatctcga	17641065
aagaaagaaa	gaaattcatg	tataatcggt	aaaatgaaaa	tgcattaaac	tcatcaatca	17641005
aaaggcagag	actctcagat	gagattttaa	aacagggctg	ccacctttgc	aggtagggga	17640945
catttttgca	ccagtcacga	tgagtctggt	gtggataagt	cagcagctag	tatggcccaa	17640885
ggaaccaatt	tctgaacaga	acctcacatg	tgctgagcct	gggcttaagg	gcagggcagg	17640825
gtgtccatgt	gtgtaggcaa	gacccagagg	aggcagtgaa	atctgacatt	gccgacacag	17640765
atctccacac	ccccagggca	gtgtctcagc	ttcagtgcct	cttctctcct	ttgagtcccc	17640705
ctttttgag	ctcttggtgc	tcttttcacc	ttagttttgg	gtggaatgag	gctgagcagt	17640645
gctgaatctg	acagaccagt	ttccagtctt	gcctgggtgc	cacagtcttg	tcctgagcct	17640585
cagtttccct	tctctataaa	ttgaggccat	ccatgtctct	ctcccagagg	ccatcaggcg	17640525
gaagggtggag	ctggagtggg	gcacagagga	tgatgagtac	ctggataagg	tggagaggaa	17640465
catcaagaaa	tccctccagg	agcacctgcc	cgacgtggtg	gtatacaatg	caggcaccga	17640405
catcctcgag	ggggaccgcc	ttggggggct	gtccatcagc	ccagcggtag	gtcctgaccc	17640345
ttggggccac	gggagggtct	gctctatgga	ctcagcagca	gcaggaaaagg	tgggcggcct	17640285
catgtcaggg	aggagatgga	ctgaagcaac	agcagtttgg	agcaggggcta	gccctgcagc	17640225
aggacttcct	gacaccatgg	gggtctggcc	tgctgagtc	accctcctct	tcccctaaca	17640165
gggcatcggtg	aagcgggatg	agctgggtgt	ccggatgggtc	cgtggccgcc	gggtgcccct	17640105
ccttatgggtg	acctcaggcg	ggtaccagaa	gcgcacagcc	cgcacattg	ctgactccat	17640045
acttaatctg	tttggcctgg	ggctcattgg	gcctgagtc	cccagcgctt	ccgcacagaa	17639985
ctcagacaca	ccgctgcttc	cccctgcagt	gccc			

- 1 -

## SEQUENCE LISTING

<110> Novartis AG  
<120> Histone Deacetylase-Related Gene and Protein  
<130> Case 4-32094A  
<160> 4

<170> PatentIn version 3.0

<210> 1  
<211> 347  
<212> PRT  
<213> Homo sapiens

<400> 1

Met Leu His Thr Thr Gln Leu Tyr Gln His Val Pro Glu Thr Pro Trp  
1 5 10 15

Pro Ile Val Tyr Ser Pro Arg Tyr Asn Ile Thr Phe Met Gly Leu Glu  
20 25 30

Lys Leu His Pro Phe Asp Ala Gly Lys Trp Gly Lys Val Ile Asn Phe  
35 40 45

Leu Lys Glu Glu Lys Leu Leu Ser Asp Ser Met Leu Val Glu Ala Arg  
50 55 60

Glu Ala Ser Glu Glu Asp Leu Leu Val Val His Thr Arg Arg Tyr Leu  
65 70 75 80

Asn Glu Leu Lys Trp Ser Phe Ala Val Ala Thr Ile Thr Glu Ile Pro  
85 90 95

Pro Val Ile Phe Leu Pro Asn Phe Leu Val Gln Arg Lys Val Leu Arg  
100 105 110

Pro Leu Arg Thr Gln Thr Gly Gly Thr Ile Met Ala Gly Lys Leu Ala  
115 120 125

- 2 -

Val Glu Arg Gly Trp Ala Ile Asn Val Gly Gly Gly Phe His His Cys  
130 135 140

Ser Ser Asp Arg Gly Gly Gly Phe Cys Ala Tyr Ala Asp Ile Thr Leu  
145 150 155 160

Ala Ile Lys Phe Leu Phe Glu Arg Val Glu Gly Ile Ser Arg Ala Thr  
165 170 175

Ile Ile Asp Leu Asp Ala His Gln Gly Asn Gly His Glu Arg Asp Phe  
180 185 190

Met Asp Asp Lys Arg Val Tyr Ile Met Asp Val Tyr Asn Arg His Ile  
195 200 205

Tyr Pro Gly Asp Arg Phe Ala Lys Gln Ala Ile Arg Arg Lys Val Glu  
210 215 220

Leu Glu Trp Gly Thr Glu Asp Asp Glu Tyr Leu Asp Lys Val Glu Arg  
225 230 235 240

Asn Ile Lys Lys Ser Leu Gln Glu His Leu Pro Asp Val Val Val Tyr  
245 250 255

Asn Ala Gly Thr Asp Ile Leu Glu Gly Asp Arg Leu Gly Gly Leu Ser  
260 265 270

Ile Ser Pro Ala Gly Ile Val Lys Arg Asp Glu Leu Val Phe Arg Met  
275 280 285

Val Arg Gly Arg Arg Val Pro Ile Leu Met Val Thr Ser Gly Gly Tyr  
290 295 300

Gln Lys Arg Thr Ala Arg Ile Ile Ala Asp Ser Ile Leu Asn Leu Phe  
305 310 315 320

Gly Leu Gly Leu Ile Gly Pro Glu Ser Pro Ser Val Ser Ala Gln Asn  
325 330 335

Ser Asp Thr Pro Leu Leu Pro Pro Ala Val Pro  
340 345

&lt;210&gt; 2

&lt;211&gt; 1755

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```
agctttggga gggccggccc cgggatgcta cacacaaccc agctgtacca gcatgtgcca      60
gagacaccct ggccaatcgt gtactcgccg cgctacaaca tcaccttcat gggcctggag     120
aagctgcatc cctttgatgc cggaaaatgg ggcaaagtga tcaatttcct aaaagaagag     180
aagcttctgt ctgacagcat gctggtggag gcgcgggagg cctcggagga ggacctgctg     240
gtggtgcaca cgaggcgcta tcttaatgag ctcaagtggc cctttgctgt tgctaccatc     300
acagaaatcc cccccgttat ctctctcccc aacttccttg tgcagaggaa ggtgctgagg     360
ccccttcgga ccagacagg aggaaccata atggcgggga agctggctgt ggagcgaggc     420
tgggccatca acgtgggggg tggcttcac cactgctcca gcgaccgtgg cgggggcttc     480
tgtgcctatg cggacatcac gctcgccatc aagtttctgt ttgagcgtgt ggagggcatc     540
tccagggcta ccatcattga tcttgatgcc catcagggca atgggcatga gcgagacttc     600
atggacgaca agcgtgtgta catcatggat gtctacaacc gccacatcta cccaggggac     660
cgctttgcca agcaggccat caggcggaag gtggagctgg agtggggcac agaggatgat     720
gagtacctgg ataagggtga gaggaacatc aagaaatccc tccaggagca cctgcccagc     780
gtggtggtat acaatgcagg caccgacatc ctcgaggggg accgccttgg ggggctgtcc     840
atcagcccag cgggcatcgt gaagcgggat gagctggtgt tccggatggt ccgtggccgc     900
cgggtgcca tccttatggt gacctcaggc gggtagcaga agcgcacagc ccgcatcatt     960
gctgactcca tacttaatct gtttggcctg gggctcattg ggcctgagtc acccagcgtc    1020
```

- 4 -

tccgcacaga actcagacac accgctgctt cccctgcag tgcctgacc cttgctgccc 1080  
tgctgtcac gtggccctgc ctatccgcc cttagtgtt tttgtttct aacctcatgg 1140  
gggtgtggag gcagccttca gtgagcatgg aggggcagg ccatccctgg ctggggcctg 1200  
gagctggccc ttcctctact tttccctgct ggaagccaga agggcttgag gcctctatgg 1260  
gtgggggcag aaggcagagc ctgtgtccca gggggacca cacgaagtca ccagcccata 1320  
gggccaggga ggcaggcagt taactgagaa ttggagagga caggctaggt cccaggcaca 1380  
gcgagggccc tgggcttggg gtgttctggt ttgagaacg gcagaccag gtcggagtga 1440  
ggaagcttcc acctccatcc tgactaggcc tgcattctaa ctgggcctcc ctccctcccc 1500  
ttggtcatgg gatttgctgc cctctttgcc ccagagctga agagctatag gcactggtgt 1560  
ggatggccca ggaggtgctg gagctaggtc tccaggtggg cctgggtccc aggcagcagg 1620  
tggaaccct gggcctggat gtgaggggag gtcaggaagg ggtacagggt ggttccctca 1680  
tctggagttc cccctcaata aagcaaggtc tggacctgca aaaaaaaaaa aaaaaaaaaa 1740  
aaaaaaaaaa aaaaaa 1755

&lt;210&gt; 3

&lt;211&gt; 1044

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

atgtacaca caaccagct gtaccagcat gtccagaga caccctggcc aatcgtgtac 60  
tcgccgcgct acaacatcac cttcatgggc ctggagaagc tgcattcctt tgatgccgga 120  
aaatggggca aagtgatcaa tttcctaaaa gaagagaagc ttctgtctga cagcatgctg 180  
gtggaggcgc gggaggcctc ggaggaggac ctgctggtgg tgcacacgag gcgctatctt 240

aatgagctca agtgggtcctt tgctgttgct accatcacag aaatcccccc cgttatcttc 300  
ctccccaact tccttggtgca gaggaagggtg ctgaggcccc ttcggaccca gacaggagga 360  
accataatgg cggggaagct ggctgtggag cgaggctggg ccatcaacgt ggggggtggc 420  
ttccaccact gctccagcga ccgtggcggg ggcttctgtg cctatgcgga catcacgctc 480  
gccatcaagt ttctgtttga gcgtgtggag ggcattctcca gggctaccat cattgatctt 540  
gatgcccacg agggcaatgg gcatgagcga gacttcatgg acgacaagcg tgtgtacatc 600  
atggatgtct acaaccgcca catctaccca ggggaccgct ttgccaagca ggccatcagg 660  
cggaagggtg agctggagtg gggcacagag gatgatgagt acctggataa ggtggagagg 720  
aacatcaaga aatccctcca ggagcacctg cccgacgtgg tggatataca tgcaggcacc 780  
gacatcctcg agggggaccg ccttgggggg ctgtccatca gcccagcggg catcgtgaag 840  
cgggatgagc tgggtgttccg gatggtccgt ggccgcgggg tgcccatcct tatggtgacc 900  
tcaggcgggt accagaagcg cacagccgc atcattgctg actccatact taatctgttt 960  
ggcctggggc tcattggggc tgagtcaccc agcgtctccg cacagaactc agacacaccg 1020  
ctgcttcccc ctgcagtgcc ctga 1044

<210> 4

<211> 23434

<212> DNA

<213> Homo sapiens

<400> 4

ctacacacaa cccagctgta ccagcatgtg ccagagacac gctggccaat cgtgtactcg 60  
ccgcgtaca acatcacctt catgggcctg gagaagctgc atccctttga tgccggaaaa 120  
tggggcaaag tgatcaattt cctaaaaggt atggaaggtc ccccttggac tctcatctgc 180



ttcctccaac ccacctgtcc tctccgtcct catccccaac ataagcctca ggctctctcc 240  
catcttcagt ttcagccctc ggatggcctt ccacccatgc ttcgcgcca aatgattttt 300  
ccaacacaga ctccaatca cgatatgatg tccctgactc agactctccc tggctcccca 360  
tctgtgggc ctaagtctg cctctgcca agaggcctag tggaaaggta gctgattact 420  
gatgggcaca gggaaggta agcttgagg agtccatttc ctaaggttca gagagtcagg 480  
aggtagagca cctccaccgc acctctcttg attacagatg ggggaaattg tgcctagaa 540  
tgattaggaa acatgtgcac ccaattccag tccagtcctc acagcagccc tcggggtagg 600  
caccacaatc gcagcagagg ctccaggagct cactgtaacc tccgcctttc aggttcaaac 660  
aatttttctg cctcagcctc ccaagtagct ggaattacag gcgtgagcca ccacaccgg 720  
ccctgatttc ttaatatggc actcattata agattgtaa agcccacctg tagaccgaac 780  
tgggcacact ggctgcctgc ttgtgacctc tttccaggga aggacacagc tcccattagt 840  
ggctgaagta acacagttac aagaggcgga gttgggtttg gaactcagag ctccaggcgc 900  
cctaccttta gggctcatcc ccttgagcaa aatgatgctt cgaagagcat atcgtttta 960  
ctgtgggttg taatcaaggg gcctgattta ggtgggaaat tcacttaaac ttgttttaaa 1020  
aggaaacatt atgtcatcaa aatgggaaaa ggcagtttca cttgccataa ataggctatg 1080  
gtaaaaaagt aaatgcaatg aaaacaacag tataattcaa tccaggctgg ttactattgc 1140  
ctgcaggctg tgagactgat tagtggtttg aacggaagat gagcaaagca caggcagggtg 1200  
ttgcgaggcc atgccacact gagcctcctg taatatcatc agaaggtgga gggaggccgg 1260  
gcgcagtggc tcgtgcctgt aatcccagca ctctgggagg ccaaggctag gagaacactt 1320  
gaggccggga gtttgagacc agcttgggca acatagcaag atcctgtctc tacaaaataa 1380

aaataaaaaa cttagctggg ggtggtggta tgcacctata gtcctagcta cttgaaatgc 1440  
tgaggcagga ggatcacttg agcccagaag ttcgaggggtg cagtgaagcta tggttgtgcc 1500  
actgcactcc agcctgggct acagagcaag accttgtctt gcattttattt atttgtttat 1560  
ttattttattg agacaggggtc tcaactcccat caccagggct agagtgcagt ggcggaatca 1620  
aggctcattg ccacctcaac ctccctggct taagtgatcc tcccacctca tgtttttgat 1680  
attttgtaga gatgcggctc cactatgttg tctagggctg tcttgaactc ctgggctcaa 1740  
gcaatccacc tgctcaacc tcccaaagtg ctgggattac aggcgtgaac caccacacct 1800  
ggccaagacc ctgtctcttt aaatgaatta aaaaaaaaaa aagggcgggg ggaagggtgga 1860  
gggggaattc ctaagaagag tttttctcac tctgaggggtc aacatccctg acccttgtgc 1920  
cacctgctcc tgaagggtgt ctagcacacc tgagctctcc ttgtgactat cagtggcttg 1980  
ggaaacatgg ggattgctgt gtgtacgatg ttcattgctc cctggccaga gggactggcc 2040  
actgtccaca gtggctgggg aggctacccc ttctcagaag gccacaagc cagcagtgcc 2100  
tacctacccc tggggcaggg gctgccacag gccaaagtctg cagcctgtgg gagggctctg 2160  
ggctggccct ggccttgagg tcagtgggga agcaggatgc tccctctgtg gtttcagaag 2220  
agaagcttct gtctgacagc atgctggtgg aggcgcggga ggcctcggag gaggacctgc 2280  
tggtggtgca cagaggggc tatcttaatg agctcaaggt acaggatgtc gggcctgggg 2340  
ggctgcgggc ctggggcagg gggctgctgg ccaggagtgg ccagaggcag gaggtgactc 2400  
agcctgggga agccaagtct cacagggcac ccattcatgt ccctagtgtt ggaggaacat 2460  
gggagtctgt ggtccccaag agaaggagag aggtcataaa aaggcagacc tcagtttggg 2520  
ccaggccact ctgaggggtg tgcctcccc ttctccaggg cgtatgaaag cttcataga 2580  
attttaggct tctacattat gactttcaag ctgtgctctg tcgacacgcc tccgagacct 2640

cagccctgt cctccaacca tacatagctc tttcactttg gtctattttg tttgtttgtt 2700  
tggtcatttt tttgttggtt tttgttcttg aaatggagtc tcaactctgtc gccagggtg 2760  
gagtgcagtg atgtgatctc ggctcattgc aacctccgcc ttccgggttc aagcaattat 2820  
cctgtctcac cctcctgagt gagtagctag gattacaggc gcgtgccacc atgcctggct 2880  
aatttttttt gtattttagt agagatgtgg tttcgccgtg ttggccaagc tggctctgaa 2940  
ctcctgaact caggatcatc gccacctcg gcctcccaa gtgctggggt tacaggcgtg 3000  
agccaccgca cccaccctat tttttatatt gggctgaagt ttaagactct ggtctaagta 3060  
cttctgctga agttttgttg aaaattgttg gtctaaaaac taatttgaaa ccctcagggc 3120  
tcagcagaga agagaaacaa gtgggagggc cgggtgtaga gtctgaggtg aactcctgcc 3180  
ccttcccaag gggcggtcc tcagctccac tgtgggccc gcatggccag agcacctggt 3240  
cttcaaagag aagccaggaa tccagattat taagtacat ttcctgattt tttttttgag 3300  
actgagtctc gctcttggtg agcaggtga agtgaggtg cacgatctca gtcactgta 3360  
acctccgct cccgggttca aacaattttt ctgcctcagc ctccgaagta gctggaatta 3420  
taggggtgag ccaccacacc cggccctgat ttcttaatgt ggcactcatt ataagattgt 3480  
aaaagcccac ctgtagacca aactgggcac actggctgcc tgcttgtagac ctctttccag 3540  
agaaggacac agtcctatt agtggctgaa gttctgaggg ctgaggcatt cagttcagtg 3600  
ctctttgtag gaacagaggg gaggttggg cgggggcttg cattggaatc tggtagtgc 3660  
agcctgcctt ggtgggggtg gggtcagga tgcctcaggt tatctgcccc aagagtgtgg 3720  
gagccctgac cccaggctc cctggctgag ctcacctag actcagagcc acagtggatg 3780  
cctgaggcca gcaggccct ctgctccaca ggtggaaaag cctaggtcca gaaagaggct 3840

gtgctcaagg tcacctggga agttggccgg gccttgggga gaccctggc aggtcatcca 3900  
gtccagtctt ctaggttccc agtcagggt gctgcctccc tgetcccaa ccgcagcctg 3960  
aggtgtgaga attctagata gggccacgac agtgtgagca catgaaagat taccaggaag 4020  
aggttgaaac ctggctcctg ggagagagag ggggtgtgagg ccttggcagg aagcccagtg 4080  
cttggctgcc ctggtttctt ggggcccagg catgcgtggt cacagtccac agcctagggc 4140  
tggggcagga ggacatgcct gccagagtcc cgagggtgag ggaaggaag ggacaggagg 4200  
cgctcagctg gggcaggag aaacaaaac agaatggtgt gattgaacca ggctgggggt 4260  
ggggggccta ggttccaggg cccacccat ttgaggggcc ttcaggggaa ctgtgttggg 4320  
caggctgcat gcctggcctt ggtccccaa aagcctgaaa gcagcttact atgtgatata 4380  
taataatata aaatagctgg gtgtagtggc atgcacttgt agtcctagct acttgggagc 4440  
ctgaggcagg agaccttgag ccagaggatt tgaagctgta gtgagctatg attgcaccac 4500  
tgcactccag ctggtatgac agagtgagac tgtctcttaa aaaaaataat aaaagtatta 4560  
acaggtagag toccaagtag aaaactgagg ttgagggtag gaggagaatt caggatatgc 4620  
cactgaaaaa gttaaccaag atggtgatcc agctgcatat ttggcttga gctccctggc 4680  
agtcagaaca aaaggagaaa catgatggtt tctacggcac ctattaagat gaagaagtag 4740  
gccgggtgca gtgactcatg cctgtaatcc cagcactttg ggagaacgag gcgggcggat 4800  
cacttgaggt cgggagtttg agatcagcct ggccaacatg gagaaaccct gtctctacta 4860  
aaactacaaa attagccagg catggtagtg catgcctgta atcccagcta cctgggagge 4920  
tgaggcagga aaatcacttg aacctgggag gtagagggtg cagtgagccg agattgcgcc 4980  
attgcactcc agcttgggca ataagagtga aactccatct caaaaaaaaa aaaaaaaaaa 5040  
aaagaaaaag atgaagaagt agtcagtcac tcaacacatc tgtattgaat gccaaactgta 5100

cagagagaat aagacagcag ggctctctgc caccatggat ttgcatttga gtcgtggaag 5160  
attaaaatta aggaagcaac cacccaagag catttttagag agcaccaagg gctatgaaga 5220  
aagtgaaaaa tagagggtaa ttggatggtc agggagggcc tcacagagga ggtgatgttt 5280  
gagttgagac taaacaaagg agcaggtgat actcatgtag aggtgttttt tttttttttt 5340  
tttttttttg gagaaggaat ctgcttttgc tgcccaggct cgagtacagt ggtgcgatct 5400  
cagctcacag caacctctgc ctcttggttc aagcgattct cctgcctcag cctcccaagt 5460  
agctaggatt acaggcacct gccaccatgc ccggctaatt ttgtatttt tagtagagac 5520  
ggagttttca ccatgttggc caggctggtc tcgaactcct gacctcaagc aatccatctg 5580  
cctcggcctc ccaaagtgc gggattacag gcatgagcca ctgctcctgg ccctcatgta 5640  
tagctttgaa ggaagaatgt ttcagaatcc caggcctgga ggggtggagg gacttgatct 5700  
tccaaagggg agaagaatgc ttgggaggcc ggatggaagg gaataaaaca ttgtggctcg 5760  
tacacgggtgc agttagggag gccagagccc caggccacac aaggtcttgc aggccgtggg 5820  
aggagtgtat atgttgttcc agggaccttg gacagtcacg agggggtttt cagcaggagg 5880  
gtgatatggt gtgacatgcc ctgtctgcc aggtgggacc caagcccgtt tcagacatca 5940  
tctggcacct aaggctgcag ctgaggaaca tctccacct ccctgcagat gtctgcaatg 6000  
tttcttttct ccttcctctg ctgtgggcgc ccagagagtg ccctagagag tccttcagg 6060  
ttctcaggct gcttttcctt ggtcattctg tgtgtgctgt gtaacatcca ccgtctcccc 6120  
tgctcatcc cattctaccc ccaaccctg cctggggctc atgcctgact ctgcactgg 6180  
gtggcctttg atacttaata aacagggcac tgaaggagaa gcaggagctg gacgtttgca 6240  
agatgtcaat tcagggaac ccatgtttat caagctcctg ctgtgtgcaa ggtccagggt 6300

tggccctct gagggtagct gttgagctcc ccagtgcgcc agcactgggc tcttgccttt 6360

ggttgattct cgggtgacag tttgccatgg agtgctcggtt agtgctgggc agcatctgac 6420

atcctgcgcc tgtgcactct gcaactggaca gtgctcagaa cacgtggatc cagcaagtgc 6480

tcagagggca ccactctgtg atctaggtgc tgcagggatg ggatggagca aaagaccaca 6540

tccttttct gctggagctg gcatttaggt gggagagtca gacaataaat gtaataatta 6600

agtaatgaga taatatgtta gatggtgctg agtgctctga agaaaggaag ggacagcaga 6660

aaaggggtgg ggagagctgg tgagaggatg gcagttttaa atcaggagtc aggaaagggc 6720

ttactacctg tgatcacagg tgacatgtgg gaaggagtg agggagtggg tgatgtggtc 6780

atctggggaa gggcattcca agcagaagaa acagcaagtg caaagatccc agggcagaac 6840

tatctgtcat gagttccagt atagtgtgga gagaaggaga cacagaccat agctccatgg 6900

agcacctgga gggaccctgg agagtctcta ggggagtgag ctctctcttg tctccaactc 6960

tctcttctct tccctgaggg gctcctctct cctttaaaaa aaaatttttt ttaattgtgg 7020

taaaatttac ataacaaaat tcgccattaa ccactttaaa ctgtacagtt cagtggcctt 7080

tagtccattc acaaagtgtc gcaaccatca tctctagttc caaacatttt catcactcca 7140

aaaggaaacc ctgtgtcctt taaacacttg ctccccattt atccccccaa gtcccccttg 7200

taatcactca cctgcattct ctctctatgg atttgctat cctggatatt tcatataaat 7260

ggaatcatac aatatgtgac cttttgtgtc tggcttatct cactaagcac agcgttttca 7320

acattcatct gtgttggtgt gtagcatgta tcagtacttc attccttttc acagcagaat 7380

gatattccat tgtaaaacac tacatttttt ttatccattc attagtttat aggccttttg 7440

gctattgtga gtagtgtgtc tgtggacatg tgcatacgag tatttattag aatacctggt 7500

ttcagttatt tggggtatat acctaggagt agaattactg ggtcacatgg taattctggt 7560

taattttctg aagaaccatc aaggtgatct ccacgggggc tgcaccattt ccaccagtaa 7620  
tgtaccaggg tcccaatttc tctacatcct tttcaatgct tgttattttc tgggtgtttt 7680  
ttttttcccc ccagtggtgg ccatcttact ggatgtgaag tggatatctca tggttttaat 7740  
ttgcatttac ctaatggcta attaacactg aggatctttt catgtgctga ttggctattt 7800  
gtatatgtca tttggagaaa tgtttattca agtcctttgt ccatttttaa aattggcttg 7860  
tctttttggt gagttgtagg gttctttata tattctggat attatttaat ttgtaaataa 7920  
ctcctcccat tctgtgggtt gtcttttttt tgatagtgtc ctttgatgca caaaaatttt 7980  
agttttgctg aagtccaatt tatctttttt tccttttctt taggtgtcat atctaagaat 8040  
ccattgccaa acccaaggtc atgaagggtt accgcatgtg ttttcttcta agagttttat 8100  
agttttcact tatatttagg ccttgataaa ttttgagtta atttttgtat atgtgtgagg 8160  
caagtccaac ttcattgttt tgtactcaga tatccagtta tcccagcacc atttgttagg 8220  
ctgtttttcc cctgttgaat ggtcttggtg cctttgtaga aaatcaactg gccatagatg 8280  
tatggattta tttctagact ctcaattcta ttcatttttt tggtttggtt gtttaagaaa 8340  
gggttgcatc ctttcgacag ccagggtgg agtacgggtg ctccatcttg gctcactgca 8400  
acctcgtct cctgggttca agcaattctc ccatctcagc ctcccaggta gctgggacta 8460  
caggcgtgtg ctaccatgcc tggctaattt ttgtgtttct tggtagagat ggggtttcac 8520  
catgttggtt aggcgtgtcc tgaattcgtg acctcaagtg atttgctcac ctgggcctct 8580  
caaagtactg ggattacagg catgtgtgag ccactgcgcc cagccaattc tattcatttg 8640  
atctatatgt caataccaca ctattttggt actgttactg tggcttactg tggttattgt 8700  
ggctttggag caaattttga aattccagat tgtgaggcct ccaactttgt tctttttttt 8760

tttttgagac gcagtctcgc tttgtcgcct atgctggagt gcaatggcgc gatctcggct 8820  
cactgcaacc tccgccttct ggtttcaggt gattctcctg cctcagcctc ccgagtagct 8880  
gggattacag gcgcccggca ccacgcctag ctaatttttc tatttttagt agagatgagg 8940  
tctcaccatg ttggtcaggt tggctcctc ctcctgacct catgatctgc ctgcctctgc 9000  
ctcccaaagt gctgggatta caggcatgag ccaccgtgcc cagccaactt tgttcttttt 9060  
taagatcggt ttggctgttt gaggtccctt gagattccat gtgaattata gcatcaactt 9120  
ccattttttg caaaaaaggc cattgggatt ttgacaggaa ttgcattgag taaattgctt 9180  
tgaggagttt tgccatctta acaatattcg gtctttcaat ccatgaacat gggatgtctt 9240  
tccgtttatt tatgtcttta atttctttca gcaatgtttt gtagctttca atggacaaat 9300  
cttgcacctc ttggttaaat ctattcccat gcattttatt cttttcgaag ttattataaa 9360  
tgaaattggt tgaatttctt ttaagattg ttcattgctg gtatatacaa taatcagttg 9420  
tatagaaata caactgattt ttttgtgtg atcttgtatc ctacaacttt gctgaatttg 9480  
tttcttagca tttttttctt tttttttttt tttttttttt ttttagacag agtctctctc 9540  
tgttaccagg ctggagtgcg gtggcatgat ctcggctcac tgcaacctcc gcctcccagg 9600  
ttcaagcgat ttttctgcct cagcctccca agtagctggg actgcagggt catgccacca 9660  
tgcccagcta atttttgtat ttttagtaga gatgggggtt cgccatgttg gccagtgtgg 9720  
tctcgatctc ttgacctcgt gatctgcccc cctcggcctc tcaaagtgtt ggtattacag 9780  
gcatgagcca ctgcgcctgg cctgtttctt agctttaata gttgtgtgtg tgtgtgtgtg 9840  
tgtgtgtgtg tgtgtgtgtg tgtgtgtatt ctttaggata ctctatatat aacatcatac 9900  
cgtctgtgaa gagaggtagc ttcccttcca atttgatggg cttttattta tttttcttgc 9960  
ctaattcctc tgattggaac ttccagtact atgttaaata gcagtagtgg agcaggcata 10020



tttgtcttgt tcctgatctt agacagaggg ctttcaatat ttaccattg agtataatgt 10080  
cagctgtggg gttaaatttt ttaacgcctt ttatcatgtt gagggagttc ccttctgttc 10140  
ctagtttgtt gagtgatctt atcacaaaag gctattgaat tttgtcaaag gctttttgtg 10200  
catcaactga gagatcgtgt tttcccttc tctgcttttg ctcccttct actggtagaa 10260  
aggaccacc taaagcaagc agtgggcgcc ctagaggggt tacagcctag ctctccctg 10320  
agagcagttc ttggtttgaa cctgagggca gcgggtccgc ctgaggaaac caggtgtctg 10380  
gaaggtgaag gcttgtggag ctgagtagat ggggcagtag gtcccagaga tatggccagc 10440  
cccagtcag tcctgtcttc tgtggagtcc cacagaggct gacgaggtat gggggccctg 10500  
atagctggct acatgcaggc catgccctt ggcggtgggt ggcgtcagtc tggggcagac 10560  
ctcccatgct cacatagtgt gtcattcac ccagcactgc cttaggttgg gctccctaga 10620  
atggtggctc ttaaacccca gcaagtatct gaaacactgg agggcttgtt ccagcagatg 10680  
gctgggcccc tcccagagtt tctgatccat gttgtcttgg gtagagactg ggaatctgca 10740  
tttctaatac attctcaagt gttgtggatg ctgctggtct gagaaccaca tccctagaag 10800  
cagagtctga gatggtgcag gcgatttcag atgaaccctg caagaggcac aggcagtggg 10860  
gagcgggcag agtgagcagc tgagcacaga tgtggatttg gaagtgtggc ctgagcctga 10920  
ttccatggag atctctgggg cgtgaatgtc accacagggt tgccctgcc agaagcatgt 10980  
ggcctggctg ttacaggccc ttgtcagtca tggctctcct gggatgatgc aggtgaggtg 11040  
gcttctgtca ggagaaggc tctggtgcac cagccagaaa aggggatcaa cggcatgcat 11100  
ggccagcacc tactgtgtgc caggcatggc ctgagcactg tctgcacagc agtgagcaga 11160  
cgctgtctgt cctctggag ctggcatcct tttgaggag atagatgcta atcgggacag 11220

tctgtagcct cagggagaga agtgctatct gggaagatga agccaaggtg tgggctccag 11280  
ggggccccag gtgggagtat tttatatttat ttttttgaga cagagtttca ctctgtcacc 11340  
caggtcggag tgcagtgggtg cgatcttggc tcaactgcaac ctccaccctt tgggttgaag 11400  
agattctcct ccctcgctc ctgagtagct gggattacag gcacctgcca ccatgcccgg 11460  
ctaatttttg tgtttttaat ggacaccaga tttcaccatg ttggccaggc tggctgtgaa 11520  
ctctggacct caagtaatcc gcctacctca gcctcccaaa gttctgggat tacagatgta 11580  
agccaccaag cctggctggg tgtggggatt ttagattaga tgaggaggac aggcctctct 11640  
gactggtttc cacctetaag tcctcatcca aagccttggt ttatagatga gacagaggca 11700  
cagagaagtg aattctaaat tcacatagcc agtggcagaa cccagacttg gaccagtttg 11760  
gggaacttct gagcctgtcc acccagtc tagcctcacc cacagtgcc ttgcccaggg 11820  
cgagactatc agggagcctg acctgctgga tctgggcagt cccaccgtgg catgctgcat 11880  
gtcccagaga aggtatctgt cagcagtga gcacccccca cctgccccac ccacagctcc 11940  
ctcgggggct atccctggaa gtgttggtca gaaagtgaat ctccagatgt cacctggtgg 12000  
tgccctgagc tctcctacc tgccacctcc tctgaccaca tagagcctgc tctagcccag 12060  
gccctcttcc ctctcctccc ctacccagg gaccggccac tagtccgccc caccactct 12120  
gtttatttct caccttgccc actgatgggt ggtttctcct agagcgggtgc tgccctgtgg 12180  
aaccttctgc aatgatggaa atgctcagac ctgctctgtg cagtccagtc gccactggcc 12240  
gcatgtggct cttgaaatat ggagagtgtg actgaggaac caaacttgaa tttttaaaat 12300  
tttgatgaat ttacaatcac tcgtaagtag ccacctgtgg ctggcagcca ctggattgga 12360  
tgggtctggt ctaggggtgtt ggcaaccaca tcaactgctt gtgcagaaac cactgctgca 12420  
ccaggagaag gcccaagtgc cagcctctc ttcactgccc gaagcctgct gctccgctga 12480

ggggctcgtc tcgccaacgt tggcacagca aacacacata ctttctcctg tgggggctgg 12540  
tcctgtgggc caagtcccgt gcatgtcctt ggggtggtgc acctggcccc tgcaccaggt 12600  
caggtccaat ctgtggagga taccaaggaa cctctttgag gttcccaagt gtgtcccatg 12660  
ccactgcagt tttgcagaag gttagtgtgt gtgacttaaa aggcaaagag ggcaggcaga 12720  
tcttctgaca tctgggggga gcaaagttag aatggaatat ttgctgcaga acttctcaga 12780  
gccttttagca tgctaggatg tgctgcaaatt ctccaggagg caggcggcct aagccatgct 12840  
tcccaaacga cttgccggtg gaagcctcct tgaggagtgc tgtgcgagac ccgtggctgt 12900  
ggagcacacg agagaatgcc tttctcgtgg tttgtgtcca tgctgggctc tcggtgcat 12960  
tgtcttcag tctgtgtccc ctgctggctt cccaggagg gagggaggct gtgactccat 13020  
gtgtccttc agcggctcgt ttgtttgtc attcgttcat ggaaaacctt ggttccatgc 13080  
cagccacacg cggggcctct gccgggcagt gggatgagtg tgggtgaacaa gaggagctga 13140  
tgacctcagg cagggaacctt cctttctctg ggtctgtccc gcaacataca cacacgcaca 13200  
cacgcacacg gacatacctg tgcacacatg tatacacaag acacatacac acacatacat 13260  
acactcatgg gtgtgtcctg cagctgtctg gctgtgctgg tccagctct tacactccca 13320  
ccccctccca ggccctgtga tgctccatg ttaccgccag agggcctggg cttgtggaag 13380  
tgggtgccccg tgggcacctc tccttcccga ccatgagtgg gacctgctc actgccttct 13440  
ctaccagagt gagggagtga tgccagctc cccgccttc agccgcctt gccggcctgg 13500  
gctgggtggc atgggcattc cccagcagtg tgggcaggct ggggtgcctg cccccagg 13560  
actatgacag aagcctcccc tgggtggccag ggcctaagcc atgaggcccc tgctggggcc 13620  
tgacttaggg tgtgtcctgc cttttgtccg gccctgagtg gcctggctac agcacctctt 13680

ggccctctga ggttcgtcac cctctgcca tcacacccat cctggccac cctctccctg 13740  
cctgtgcct gctgtctgtc attgaacatg ctctgtttc tcccatccta aaactcctcc 13800  
tcctggttgg tgaacgcaat ggccacactt cccactttcc tctcatggaa tgtctgcagc 13860  
ttggtgcctc cctccacctg ctcttccag ccacctctc tccacctggc ctctgagca 13920  
ctgcacctta ggtctttcca catctcaccc tgtcccaggg aagcccttga tcgtcccag 13980  
gggttctctc tctgggcctt gcccttcagc atgggaagcc tgcagtcca acccagccct 14040  
tcacctcca ctctcccacc cctgttctga gctccagtct cacttaaacc tcagctgtct 14100  
cacctggctg ccccgagggc tgacttgcc catagagagc agaacctagt gccgcctctg 14160  
tacctgctt caggttcacc tccaagtgc attacctca caggccccag acccgacacc 14220  
tgggccctct acccctgtc cctgcatgct gcctgcta atctgctct cttaccaccc 14280  
cagacccttc ttatctcatg ctctctctt agggctgcta cttctctatt cctgttcccc 14340  
taattggttc tccttctgc agctagtgc gcttgggaca gcaccatcta tggttcccta 14400  
ctgccctgac gacaatgtgt gagcctgtgc taggagacca ggccctgtgt gataagctca 14460  
gcctgccctg ttccagtgc acccaccttc tctagatcat ggactcaact ctctgccac 14520  
agataccttt ttcccttgac ctctgcatct ggataactcc tattcactct tcacctctg 14580  
caaatgccat cccccaga aagcctctt aataaccccc acccagttct cctcttcac 14640  
accacactca tcacactgca aataagtgtc tgcaagtgtc ctggcatgag aatgggcct 14700  
ccagtgccca cctggggcac ctagcaggca cttagtaa atttacaaag tgagtggctc 14760  
tgcctcgcgt ggggtggggag cagggatgcg ttttcagcca ggagatggct tggggtttg 14820  
gttcagctgg gcagccagt ccattggatat ttacctgtg cacttgagg tcacaggga 14880  
cactctgtcc tgatcttagt gcagatacct ttcaggtacc gtagaccccc ccagcctcag 14940

cagctggaga tgagggcagt gcatcccttt tgccaggaag gtccgattcc caatggacaa 15000  
agaggcaatg cagtgcgagg gagccagagg ccagggctcc cgtcccagct ctgtcagtga 15060  
ctcattgtgt ggccttggga agatcctcgc tgcctaggcc tcagtgtccc cttctgtaca 15120  
gtgggtgggc tagactaatt tgttatccca aagcagtcct agacctgcac tgctgacttg 15180  
gagccctctg cacctcctgt tctgggcaca agagggcagc caagggcctc agaacgctga 15240  
ggaaccctgg ccaactagct ttaagaaatg cattgtgtaa actgctcttt actgagccca 15300  
gagcttgcca ggagcctggg agggttgtgg ctctggctct catttctacc aaaggaagtg 15360  
tgcttgacca gggagttcat ccaagggcac ctggaaactg tcctcaaggc atttcccggg 15420  
gaaccaatth ctcacgggtt gctcagggg ggggaagcgg aggccaacag cccctgtctt 15480  
tttccgcagt ggtcctttgc tgttgtacc atcacagaaa tccccccgt tatcttctc 15540  
cccaacttcc ttgtgcagag gaagggtctg agggcccttc ggaccagac aggaggaacc 15600  
ataatggtag gtggggtggg ggggcatggc tgggtgggg gcccccacac ccaggggtcc 15660  
ttctcacctc ctttgccctg gaatgcctc ctcccactta gtagttgaac agaatectaa 15720  
atattctca aggtcggca acaatgacct tttctcaaa agcctttttt cccatcttg 15780  
ggacatcaga attctcttct catcgttctt tctctatga cctcctattt gttaccgtaa 15840  
ttgctagtat ataataacc tctccacca ccaaagcggg taccctagca ctatggcttt 15900  
aaggcacacc cctcaccag tttttcttt ctttctttct ttttttttt tgagtagagt 15960  
ctcgttctgt cgtccaggct ggagtgcagt ggtgtgatct tggctcactg caacctctgc 16020  
ctcctaggtt caagcgattc tcttgctca ggctcctgag tagctgggac tacaggtgtt 16080  
cgccaccatg cctggctaatt ttttgatatt ttagtagaga cggggtttta ccatgttggc 16140

caggctggtc ttgaactcct gacctcaaat gatccactca ccttggcctc ccaaagtact 16200  
gggattacag gctttgagcc accatgcccga gccctaatac acccaaaatt aagatggaga 16260  
actgatcctc catgacttca gtgatgaata agcctccaag tctccccac tgcgggtgtg 16320  
gcaacaaaga atccccacag caaaattagg ttccacattg tgtgtgtggt ttttttaaaa 16380  
aaatgtgcca cacactgcct agttatttgg agatagagga atgtttcaca tgcaaatgta 16440  
tgaggatcta acccagccct ggatcactac ctactgatcc cctacagtcc tgttatgttt 16500  
gtaaatttgt actttttcct ttagcttagt agaataattac tgcccatccc caaaactatg 16560  
atttcctgga agatttcagt atttagtcta ctatatttct ttttttgctt tttttttttt 16620  
tttttttgag acagagtctc actctgtcct ccaggctgga gtgcaggggt gtgaccttgg 16680  
ctcactgcaa cctctgcctc ctgggttcaa gtgattctcc tgcctcagcc tcccagtagt 16740  
ctgggattac aggcacacgc cactctgcct ggctaatttt tgtattttta gtagagacgg 16800  
ggtttcacca tgttggcgag gctggctctg aactcctgac ctcaagtgat ccgcctgcct 16860  
cggcctccca aagtgtctggg attacaggcg tgagccactg cgcttgccc agtctactgt 16920  
atttctgtga gcaaaacttt gcctattttc cctttgaaag ccatatcaaa attattgtca 16980  
gctcatatgt gatggatgat aagtactttt attttttcca gtttccttgc acaatttcaa 17040  
aggtgcttat gcactgtaca tctcatatgc cagccaagct ggcacttact tcttgactg 17100  
ttgcttgggg tagggagtcc cttctatacc cctgccttgt agctcagctc atccttcccc 17160  
cagagctggc tagaagcagt gtttatggaa tgagtgcata aatcagtga tgaatgactg 17220  
gtggatcggc tgcctgcgcc cctcaccct ctgcttgtct ccaaaggcgg ggaagctggc 17280  
tgtggagcga ggctgggcca tcaacgtggg tgagtgtctg gaatgtcctc gggaatgtcc 17340  
agccccgctt ggtggaactg gcctgaaagg gggctggggg agggcgggag gatcctggag 17400

gtggcagctg tgaattcaga agctctgggt ttcccaagtc accctagcct ccttgtggag 17460  
tggcctggag gttgatgtgt agcctcctag gtacctggga gagactgacc agtgccctca 17520  
tctgacgtgg gatccttgtc taaggagggt cccgggtgggt tccccagccc cctctttgctg 17580  
tacttccggt ggcagggagc ttctccctt ccagagagcg tgtgccatcc ttgggcagct 17640  
cagcatgggtc tgaagcctgc cttgtgtctt ccctgaagga ctccacctgt gtccctggggc 17700  
ccaggacagc ccacagaggc ttgggtcatgt tgggttgggt gggcacatcc tgggtcaata 17760  
ccaccacctt ctcaagggtc cagagggccc gtgtcccca gcccccttga atctccaca 17820  
agattggctc atgggagggc tgcacgggag tctcccttgt ccctgtcatt gtccctcctg 17880  
gaggcacagc acttgacaat ttacaaagct ctttttcacc aggtcttttt tttctttttc 17940  
gagacgtagt ttactcttg ttgccaggc tggagtgcaa tggcgcgatc tcggctcacc 18000  
gcaacctccg cctcccaggt tcaaacaatt ctctgcctc agcctcctga gtagctgaga 18060  
ttacaggcat gcaccaccat gccgggctaa ttttgtattt ttagtagaga cagggtttct 18120  
ccatgttgggt caggctgggt cttgaaactc cgacctcagg tgatacgccc acctcgctcg 18180  
gcctcccaaa gtgctaagat tacagacatg agccaccacg cccggccttc acccagactc 18240  
ttatttgagc tgggcataat tgtcaggcct gtctcactga tgaggaaatg gccatggaaa 18300  
gatgcgtact ggatcgtgta gagccctaaa gcagggtccc ccagccttg gctctgaact 18360  
ctgcagggga gagtccacct tgggccactg cacagttgag gggagcccca ctctgcagg 18420  
gctgggtctc ttccatcttg gtattaccag gtgcctagca ttcagtctgg catagtaatg 18480  
atgttatgggt actctgctgc aaaaaccgg gagtgatctg tgcctgcgt gtctacagca 18540  
gggttccgag gagggcctgg atggccctcc ccatggcagg tgttactgcc tggtagagg 18600

taagagcctg gatcctgac caccctgggt ttgatcctgg ttctgccatt acctggctgt 18660  
gtgaccctgg gcaagttgct gacctcctct gtgggtcagt ctcctcatct gtaaaatggg 18720  
gatgggtgatg ctaatgcccc tcctcgggct ggagggagtc ttcagcaagc tcagttgctc 18780  
agtcagggtgt tcactgtggc tgtcttctca tcattaggag ccaacagtag cctcctgggg 18840  
gggaggagag gcaagttcct ggtatccatg gggccagctg cacactgtct gacggagcag 18900  
ttgttgggct caatttcaga gggcctctgc aattcaggcc atcccagggg ctgcaggga 18960  
gggggtatct atgggcccta gggctctgag gctgtgtctc agggttgagg ggtgatggat 19020  
cccgggctct agggccctcc tcgtggctgt aggcagtcac gaccagcaga gggcgccctt 19080  
cctgaccacc cgctttggcc actggcagaa tccgtgtggc cccatacca ccaactcttc 19140  
ctggagtggg gagccacatg gagccaggcc cagcttgggtg gggacaagga gcagctttct 19200  
gcttctggaa tgatgagcta tctgttgctt aggggtgtga gtggcactga ggacttgctg 19260  
gggacaccct gaagatgtgg ctgccttctg gcctggggat ggtgacatgc cccagcactc 19320  
agcttagttt gccaaaccag agtccgaggc acaggttcct gagagctgag cagggaggat 19380  
gctgggggag gtgaagggat ggaggagctc ctggactgag cctgggagcc tggctctgag 19440  
cagcacgct ctctgccctt ccgcaggggg tggttccac cactgctcca gcgaccgtgg 19500  
cgggggcttc tgtgcctatg cggacatcac gctcgccatc aaggtgtgtc tatgagcaag 19560  
tggggtctcg cctccaagag cctcctgga atcctcccca tagctccaaa ttaactgttc 19620  
tcaccctgaa ttatagacaa ggggcctatg ctggagcagg gagggggctt gtttgggttg 19680  
ctcagccagg ctggaactga atccagatct gacacttgct cctcttccat gttgcttaga 19740  
agggttgcct gtggtggaag ggagttatc cagcctcca cagagccagg ggactagaga 19800  
gggtcaggat ctgctgtata gccacatatt aagttgtagg aagaaggga tggctggcaa 19860



agggagtagg gagtggaaag aatgatggtg ctgatagcac ctggcagttc tgcattgctcc 19920  
aaccgcgct gtgctccagg acttactccc tgaatcctcg cagacagaca ggggcccaca 19980  
gaggtgaggg catgcaaata gcaggggcag aattggcgct ggcctctggt ctgtggggcc 20040  
ccacaactcc cctgccactc tgtgcctggc cttgtgctgg gcatcaggaa ctgactgacc 20100  
tgttccatg tgtgcctgct ctcattggggc acatagactg atggggggaa gcaggccatt 20160  
aggagaaggg ggaagcacag gagaccttc tggggaggag ggaatgaagg cttcctggaa 20220  
gagggggcat ttaggacttg gccttgtagg ataaggcaga ggttggggac tgaagtccca 20280  
gggctgtggg gattctctcc ttaacccta cacatttctt aggaatctg ggaaaatcca 20340  
gggcctgagt gaccactta cctcctgacc tatgacctt cagggcacag gacatgcccc 20400  
ctcctccagg gagccttccc tgaccactc ctgcatgcac acatggagcc ccacagctgg 20460  
agctgcacag ctctccctgg caagtacat ctttctggtg tggcctgatt acccacaagc 20520  
attaggcccc cctccccgcc cctcgccagc cagctgggag ttgctgtagg gctgggtcct 20580  
ctgtccgcc cagatcctca tgtctacct ctcctcctg gcagtttctg tttgagcgtg 20640  
tggagggcat ctccagggt accatcattg atcttgatgc ccatcaggtg agtgccctgc 20700  
aggggctgga ctcttagggg acctgccacc ccagttcca gaatcttccc ggggcaggag 20760  
agtctccctc ctcatgtccc cagggctctc acggcttctg tcttctgtct ctcgggtac 20820  
aaatgcaggg tctgtctttg tcaactctgtc caggacagcg ggctctctc attgctccc 20880  
agggctctcc ctccctctc ctgactgcc ccacatgagg ctcttctga agccactct 20940  
gatgggactg ctctcgtgtg cagagctctg ctgtgggtcc ccattgctta tgaataattt 21000  
ggggcactgc cccctgccca gagctgctga gcactggcca cctgcccctc aggcggatgc 21060

ccacacacat ggcttggtc gggcacctgg ggtcaccatt taagaactcg ggcctaggg 21120  
agtaaagtgt caaagcagag ggttacctcc tctcaggac ccctaagag gccagtgcct 21180  
ctggtcagac agggagggga cccagtgggc tccggaaggc accccctgc accattactg 21240  
ctgtggcttt gtgctagttg gggccctgcc ttgggttctt gcgacccga actcctgagc 21300  
caggtcacat gtggacagtc ctttacagtt tgcttttcac atccctgatc ccaaccagtc 21360  
ccaccacaga cttgagaggg tggcagagcg ggatttcttc ctctgatagg gaacctaga 21420  
gcactgggct tgctcaagcc catgctagaa ggtgtcgggg cctggtttta aggttgaatc 21480  
ccagctctgc cccttaacag tcatgagacc tgctgcccc gagagcaggc cgtgctgccc 21540  
tggcaaattg ggagtttctt gagggggtggg tgggtggcag agccccagcc ttgcctaggg 21600  
cacctaccg agagcggcta ctgtgacctc ccacagggc aatgggcatg agcgagactt 21660  
catggacgac aagcgtgtgt acatcatgga tgtctacaac cgccacatct acccagggga 21720  
ccgctttgcc aagcgtatgc tgctgcccct accctcatct tgggtgtgtc cttgtggatg 21780  
aggctctctc ctgagtgtct cctgtctgct aggcctgca gaagccactg cagtggttca 21840  
tagcatccct gtgaggtgat cttttccatt ttacagatga ggaaaccgag acctggagaa 21900  
gtcactcgac ccaccaaga tcacataacc cttacaataa acatgcattt gtctggcaaa 21960  
aaacaggaaa gaatgaaaga aaaaaagaa aaataggata aatttgaaaa tacgaaataa 22020  
gaaataaatt cacataggct gggcgcggtg gctcacgcct gtaatccag cactttggga 22080  
ggctgaagtg ggcggatcac ctgaggtcgg gagtttgaga ccagcctgac caacatggag 22140  
aaaccccatc tctactaaaa atacaaaatt agctggatgt ggtggcgcat gcctgtaatc 22200  
ccagctactc gggaggctga gacaggagaa ttgcttgaac ctgggaggcg gaggtttcgg 22260  
taagccgaga tcgcgccatt gcactccagc ttgggcaaca agagcgaaac tccatctcga 22320

aagaaagaaa gaaattcatg tataatcggt aaaatgaaaa tgcattaaac tcatcaatca 22380  
aaaggcagag actctcagat gagatttaaa aacagggtg ccacctttgc aggtagggga 22440  
catttttgca ccagtcacga tgagtctggt gtggataagt cagcagctag tatggcccaa 22500  
ggaaccaatt tctgaacaga acctcacatg tgctgagcct gggcttaagg gcagggcagg 22560  
gtgtccatgt gtgtaggcaa gaccagagg aggcagtga atctgacatt gccgacacag 22620  
atctccacac cccagggca gtgtctcagc ttcagtgcc cttctctcct ttgagtcccc 22680  
ctttttgcag ctcttggtgc tcttttcacc ttagttttgg gtggaatgag gctgagcagt 22740  
gctgaatctg acagaccagt ttccagtctt gcctggtgct cacagtcttg tcctgagcct 22800  
cagtttcct tctctataaa ttgaggccat ccagtctct ctcccagagg ccacagggcg 22860  
gaagggtggag ctggagtggg gcacagagga tgatgagtac ctggataagg tggagaggaa 22920  
catcaagaaa tccctccagg agcacctgcc cgacgtggtg gtatacaatg caggcaccga 22980  
catcctcgag ggggaaccgc ttggggggct gtccatcagc ccagcggtag gtcccgaccc 23040  
ttggggccac gggagggct gctctatgga ctcagcagca gcaggaaagg tgggcggcct 23100  
catgtcaggg aggagatgga ctgaagcaac agcagtttgg agcagggcta gccctgcagc 23160  
aggacttcct gacaccatgg gggctctggc tgccctgagtc accctcctct tcccctaaca 23220  
gggcatcgtg aagcgggatg agctggtggt ccggatggtc cgtggccgcc ggggtgcccc 23280  
ccttatggtg acctcaggcg ggtaccagaa gcgcacagcc cgcacattg ctgactccat 23340  
acttaatctg tttggcctgg ggctcattgg gcctgagtca cccagcgtct ccgcacagaa 23400  
ctcagacaca ccgtgcttc cccctgcagt gccc 23434



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 February 2003 (20.02.2003)

PCT

(10) International Publication Number  
**WO 03/014340 A3**

- (51) International Patent Classification<sup>7</sup>: C12N 9/16, 15/00, C12Q 1/68, G01N 33/50, C07K 16/40
- (21) International Application Number: PCT/EP02/08654
- (22) International Filing Date: 2 August 2002 (02.08.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/309,957 3 August 2001 (03.08.2001) US
- (71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (74) Agent: GROS, Florent; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
27 November 2003
- (71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ATADJA, Peter, Wisdom [CA/US]; 18 Eastbrook Road, Parsippany, NJ 07054 (US). CUETO, Maria [US/US]; 99 Clifton Terrace, Weehawken, NJ 07086 (US). GAO, Lin [US/US]; 8 Millstone Drive, Morris Plains, NJ 07950 (US).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/014340 A3

(54) Title: HUMAN HISTONE DEACETYLASE-RELATED GENE AND PROTEIN HDAC10

(57) Abstract: Disclosed is an HDAC related gene and gene product. In particular, the invention relates to a protein that is highly homologous to known HDACs and referred to herein as HDAC10, nucleic acid molecules that encode such a protein, antibodies that recognize the protein, and methods for diagnosing conditions related to abnormal HDAC10 activity or gene expression.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 02/08654

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 C12N9/16 C12N15/00 C12Q1/68 G01N33/50 C07K16/40				
According to International Patent Classification (IPC) or to both national classification and IPC				
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C12Q G01N C07K				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EMBL, EPO-Internal, WPI Data, PAJ, MEDLINE, EMBASE, BIOSIS				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>				
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	DATABASE EMBL 'Online! 29 September 2000 (2000-09-29) WATANABE ET AL.: "Homo sapiens cDNA: FLJ22237 fis, clone HRC02058." retrieved from EBI Database accession no. AK025890 XP002225132 Polypeptide and cDNA with 100% identity over full lenght. abstract <div style="text-align: center; margin-top: 20px;">-- --/--</div>	1-22		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <span style="margin-left: 100px;"><input type="checkbox"/> Patent family members are listed in annex.</span>				
* Special categories of cited documents:				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; border: none;">           *A* document defining the general state of the art which is not considered to be of particular relevance            *E* earlier document but published on or after the international filing date            *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)            *O* document referring to an oral disclosure, use, exhibition or other means            *P* document published prior to the international filing date but later than the priority date claimed         </td> <td style="width: 50%; vertical-align: top; border: none;">           *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention            *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone            *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.            *&amp;* document member of the same patent family         </td> </tr> </table>			*A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family
*A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family			
Date of the actual completion of the international search  <div style="text-align: center;">7 January 2003</div>		Date of mailing of the international search report  <div style="text-align: center;">05/02/2003</div>		
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  <div style="text-align: center;">Friedrich, C</div>		

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/08654

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online!  29 March 2000 (2000-03-29)  WANG ET AL.: "Homo sapiens chromosome 3  clone RP11-449E21 map 3p."  retrieved from EBI  Database accession no. AC027124  XP002225133  genomic sequence  abstract</p>	1-22
P,X	<p>---  DATABASE EMBL 'Online!  31 January 2002 (2002-01-31)  MEYERS ET AL.: "Human histone deacetylase  47508."  Database accession no. AAM51008  XP002225134  abstract</p>	1-22
P,X	<p>-&amp; WO 02 08273 A (MEYERS RACHEL A;  MILLENNIUM PHARM INC (US))  31 January 2001 (2001-01-31)  examples 1-5</p>	1-22
A	<p>---  FISCHLE WOLFGANG ET AL: "A new family of  human histone deacetylases related to  Saccharomyces cerevisiae HDA1p"  JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN  SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE,  MD, US,  vol. 274, no. 17,  23 April 1999 (1999-04-23), pages  11713-11720, XP002159645  ISSN: 0021-9258  the whole document</p>	1-22
A	<p>---  GROZINGER CHRISTINA M ET AL: "Three  proteins define a class of human histone  deacetylases related to yeast Hda1p"  PROCEEDINGS OF THE NATIONAL ACADEMY OF  SCIENCES OF USA, NATIONAL ACADEMY OF  SCIENCE. WASHINGTON, US,  vol. 96, no. 9,  27 April 1999 (1999-04-27), pages  4868-4873, XP002159644  ISSN: 0027-8424  the whole document</p> <p style="text-align: center;">--- -/-</p>	1-22

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 02/08654

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>KAO HUNG-YING ET AL: "Isolation and characterization of mammalian HDAC10, a novel histone deacetylase." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 1, 4 January 2002 (2002-01-04), pages 187-193, XP002225131 January 4, 2002 ISSN: 0021-9258 figure 1</p>	1-22



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.1

Although claims 11-14 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

---

## Continuation of Box I.1

Rule 39.1(iv) PCT - Diagnostic method practised on the human or animal body

---

## Continuation of Box I.2

Present claims 10, 11, 13, and 22 relate to a compound defined by reference to the term HDAC10. The use of this parameter in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is impossible to compare the parameter the applicant has chosen to employ with what is set out in the prior art. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, the search has been restricted to HDAC10 according to SEQ ID No.1-4.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 02/08654

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: —  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/08654

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0208273	A	31-01-2002	AU 7710501 A	05-02-2002
			WO 0208273 A2	31-01-2002
			US 2002164752 A1	07-11-2002
<hr/>				

**THIS PAGE BLANK (USPTO)**